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General introduction, aims and 
outline of this thesis
2Abstract
Regenerative medicine aims to develop medical devices, cell therapy and materials, 
e.g. tissue engineered constructs, to aid and enhance the treatment of damaged tissues 
and organs. The ultimate goal of these treatments is regeneration without the formation 
of scar tissue. A strategy that could lead to this goal is the use of principles found in 
embryonic development. In this thesis, we aimed to design an embryonic-like scaffold 
that may be used for the treatment of human skin defects resulting in improved skin 
regeneration. In the process leading to the design of an embryonic-like scaffold we 
studied effector molecules, e.g. growth factors and morphogens, and components of 
the embryonic ECM with a focus on glycosaminoglycans.
This chapter commences with an overview of adult skin anatomy of both mouse and 
human skin. Subsequently skin development will be described predominantly for mouse 
skin. Next, human wound repair will be discussed and the principles of this process 
are compared to scarless healing as found during embryonic development based on 
examples from multiple animal model systems. Relevant principles of tissue engineered 
constructs are discussed and the main components of these constructs described. 
Glycosaminoglycan (GAG) biosynthesis is described as GAGs are expected to be one 
of the important building blocks of the embryonic-like scaffold and as Chapters 5 and 
6 will focus on GAGs in development and disease. Finally, the aims and outline of this 
thesis are described.
Chapter 1
31.1 Skin
Skin is considered the largest organ of the human body. It protects us from the 
environment both physically and through signalling mechanisms [1,2]. In this section, 
an overview is given of the anatomy and development of skin.
1.1.1 Anatomy of mature skin
Murine skin can be subdivided in four layers, i.e. the epidermis, dermis, panniculus 
adiposus and panniculus carnosus (Figure 1) [3]. Human skin contains essentially 
the same layers except for the panniculus carnosus, a subdermal muscle layer [1]. 
The epidermis is a keratinized stratified squamous epithelium [4], which protrudes into 
the dermis by rete ridges and appendages, such as hair follicles, sweat glands and 
sebaceous glands. Epidermal rete ridges are suggested to provide a microenvironment 
for epidermal stem cells, which additionally reside in the bulge area of hair follicles [1,5] 
and may also be present in sebaceous glands [6]. Stem cells are involved in the constant 
renewal of the epidermal barrier, skin homeostasis, hair follicle regeneration and wound 
repair [2,6]. The epidermis rests upon the dermis, which consists of connective tissue 
containing fibrillar collagens. Both layers are separated by a basement membrane 
produced predominantly by the epidermal basal cell layer. In mature dermis, two layers 
can be distinguished, i.e. the papillary dermis close to the epidermis and the reticular 
dermis near the panniculus adiposus [5]. Both layers of the dermis contain various 
cell types, e.g. fibroblasts, macrophages, mast cells, immune cells, and structures 
such as blood vessels, lymphatics and nerves [5], all resting within a matrix which, 
in addition to collagen, contains elastic fibers, fibronectin and glycosaminoglycans. 
Glycosaminoglycans are thought to regulate molecular trafficking in the dermis by 
binding and modulating extracellular molecules [1].
1.1.2 Development of the epidermis
The epidermis is formed after gastrulation from ectoderm under the influence of Wnt 
signalling. Wnt signalling stimulates the expression of bone morphogenetic markers 
and inhibits cells to react to fibroblast growth factors, which stimulate a neural fate [6,7]. 
The epidermal-fated ectodermal cells will form a periderm layer 9 days post conception 
in mice and after 4 to 8 weeks of gestation in humans. The periderm is an embryo-
specific stratified cell layer separating the embryo from the amniotic fluid [1,8,9]. The 
development of the epidermis continues 12 days post conception in mice and 9 weeks 
of gestation in humans by regional stratification under the control of Hox genes and 
the transcription factor P63, a homolog of P53 [1]. P63 knockout mice show a lack 
of stratification of the epidermis and die, amongst others, due to dehydration [10]. 
Stratification is a process in which cells of the basal cell layer, resting upon the basement 
membrane, divide asymmetrically causing terminal differentiation and resulting in three 
histological distinguishable layers on top of the stratum basale, i.e. the stratum spinosa, 
stratum granulosum and the stratum corneum (Figure 2). Depending on the thickness 
of skin, a stratum lucidum is present between the stratum granulosum and stratum 
corneum. Cells are shedded at the end of terminal differentiation [2,11].
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41.1.3 Development of the dermis
The dermis (Figure 3) originates from different sources of mesoderm depending on 
the location on the embryo. Dorsal dermis is derived from the dermamyotome, a 
compartment of somites. Lateral plate mesoderm is the origin for ventral and limb 
dermis, while neural crest cells are the origin of cranial dermis [1,12]. The dermis is 
thought to have a crucial role in the development of the epidermis through various cell 
signalling processes by which epidermal cell differentiation and appendage formation is 
initiated [1,6]. In adult skin the dermis provides nutrients to the epidermis [1].
The development of the dermis will be discussed for mice. The structural development 
of the dermis in mice starts 14 days post conception when the undifferentiated 
mesenchymal cells adopt a fibroblast-like phenotype and start producing extracellular 
matrix components. At 16 days post conception the fibroblasts have matured into 
dermal fibroblasts and extracellular matrix production is increased. The dermal matrix 
subsequently matures further by the thickening of the collagen fibers [1].
 1.1.4 Development of the basement membrane
The basement membrane separates the epidermis and the dermis. It contains, amongst 
other components, type IV and VII collagen, fibronectin, entactin, heparan sulfate (HS) 
and laminin 5. The basal cell layer of the epidermis supplies and organises type IV 
collagen and laminin. Fibronectin is supplied by both dermis and epidermis [4]. The 
composition of these components may vary due to spatiotemporal development of skin 
[5]. The importance of the basement membrane has been shown in type IV collagen 
knockout mice, which die 10 to 11 days post conception due to lack of integrity, stability 
and functionality of basement membranes [13].
Figure 1 – Anatomy of murine skin. Mouse skin 
consists of an epidermis (A) resting upon the 
dermis (B). Beneath the dermis the panniculus 
adiposus (C), a fat layer, and the panniculus 
carnosus (D), a muscle layer, can be found. Bar 
is 50 µm.
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51.1.5 Development of skin appendages
Appendages are formed by a complex but organized interplay between epidermal 
and dermal cells and can be seen in the mouse embryo 16 days post conception and 
in human embryos around 16 weeks of gestation [1,8]. It is thought that the dermis 
provides the first signal to form a cluster of ectodermal cells, under which mesenchymal 
cells in the dermis assemble into a dermal papilla [1,6]. To illustrate the formation of skin 
appendages we focus on the development of hair follicles in mice (Figure 4) [14]. During 
hair follicle development Wnt signalling molecules, fibroblast growth factors and BMP 
inhibitory factors are important for the formation of the ectodermal placodes [6].
In the second stage the dermal papilla moves downward to form a hair germ which 
develops in a hair peg in stage three [14]. The leading front of the downward growing 
hair follicle is highly proliferative and interacts constantly with the dermal papilla [6]. The 
inner cell layers of the hair peg develop in an inner rooth sheath cone in stage four and 
the dermal papilla becomes enclosed in the growing hair follicle as part of the bulb region 
[6,14]. Cells above the root in the outer root sheath stay in contact with the basement 
membrane [6]. In the next stage the bulge area and sebaceous gland are becoming 
apparent by a local thickening of cells in the hair follicle near the epidermis and the 
Figure 2 – Terminal differentiation of skin adapted from Fuchs 2008 [2]. Terminal 
differentiation is started upon asymmetrical differentiation of cells in the basal layer 
resulting in four distinct layers upon the basement membrane, i.e. the basal layer, the 
spinous layer, the granuluar layer and the stratum corneum.
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6presence of sebocytes, respectively. At stage six, a growing hair becomes visible in the 
hair shaft and melanin is produced. At 18.5 days post conception in mouse, hairs can 
be found hidden in the hair shafts, corresponding to stage seven according to Paus et 
al. (1999) [14]. Stage eight of hair follicle morphogenesis is visible after birth when hairs 
emerge out of the skin [14].
1.2 Skin defects and wound repair
Skin is the first line of defence against physical harm, e.g. burns, cuts and abrasions. 
Depending on the size and depth of the wound, skin heals with or without a scar. In 
comparison with healthy undamaged skin, a scar is characterized by disorganized 
extracellular matrix [15] or a macroscopic fibrous disturbance [9]. It is the aim of this 
project to take the first steps towards fully regenerated damaged skin, resembling 
scarless healing as found in dermal wounds in early embryonic development [8,16].
Figure 3 – Schematic representation of the human dermis adapted from Kamel et 
al. 2013 [36]. The dermis consists of connective tissue in which fibroblasts reside. In 
addition sweat glands, blood vessels (capillaries) and touch receptors can be found in 
skin. The dermis rests upon the panniculus adiposus or hypodermis.
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71.2.1 Wound healing
Wound healing can be subdivided into four stages, i.e. haemostasis, inflammation, 
proliferation and remodelling (Figure 5). Upon wounding the haemostasis stage is 
initiated and is characterized by the formation of a fibrin clot, which serves as a temporal 
barrier to protect the wounded area. In addition it serves as a provisional matrix for cells 
during the repair process and as a reservoir of signalling molecules, which are released 
to start the next stage of wound healing, the inflammation stage. This stage is started 
by the release of chemotactic cues recruiting inflammatory cells, which remove death 
tissue and prevent infections [8,15,17].
In the subsequent proliferation stage, 2 to 10 days after injury, new tissue formation is 
started by proliferation of cells in the epidermal cell layer at the wound edges, which 
migrate over the injured dermis and mature by stratification, restoring the barrier 
function of skin. In the dermis the formed fibrin clot is replaced by granulation tissue 
accompanied by the formation of new blood vessels. In addition, fibroblasts proliferate, 
deposit collagen and are recruited into the granulation tissue. Part of the recruited 
fibroblasts differentiate into myofibroblasts to contract the edges to close the wound 
and deposit collagen [8,15,17]. In the final stage of wound healing (remodelling), the 
extracellular matrix is remodelled to restore skin integrity [8,15].
The ECM of healthy skin consist of a basket-weaven collagen network. The new collagen 
fibrils formed during the proliferation and remodelling phase, however, are deposited as 
densely packed bundles, which is typical for the ECM of a scar [18].
1.2.2 Scarless healing or regeneration
In contrast to adult wound healing, skin wounds in early gestation heal rapidly and 
scarlessly [8,9]. In general, the phases of wound healing are suggested to be equal to 
adult wound healing. Differences which may explain the outcome of wound healing in early 
gestational embryos and adult skin can be found in mechanical aspects, environmental 
aspects, the inflammatory response, ECM content and cellular characteristics [9,19,20].
One of the major mechanical differences between adult and embryonic wound healing is 
the method of wound closure. Wound closure in embryonic wound healing is facilitated 
by the formation of an actin ring in the leading edge of basal marginal cells of the 
epidermis surrounding the wound. This actin ring pulls the wound edges together to 
close the wound [19,21]. In adult wound healing the wound is closed by contraction 
of the dermis due to the action of myofibroblasts. The epidermis is reepithelized by 
proliferation and migration through lamellipodial crawling [19].
The environment of a mammalian embryo is filled with amniotic fluid, which is rich in 
hyaluronic acid and growth factors [9], which are suggestively beneficial for scarless 
wound healing [22]. Experiments with opossums, however, showed that scarless healing 
can also take place outside the uterus [8,23]. Experiments in sheep and subcutaneous 
transplantation of human foetal skin in athymic mice suggest that the environment may 
not be key for scarless and adult healing, resulting in a scar [9,24,25].
Inflammatory processes are important for adult wound healing. In foetal wound healing, 
however, differences can be found in the number and type of inflammatory cells present 
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8in comparison to the same process in an adult [9]. Differences include the lack of 
polymorphonuclear leukocytes and the number of macrophages entering the wound 
[8,26]. In general, during scarless healing inflammation is reduced or even absent [9]. 
These observations are supported by experiments in which the inflammatory response 
was suggestively reduced during normal wound healing, leading to a reduction in scar 
formation [9,27].
Another difference between adult wound healing and early gestational wound healing is 
the content of the ECM. For proper development, the undamaged foetal ECM promotes 
migration and proliferation. These characteristics of the foetal ECM are beneficial 
during wound repair and could explain the phenomenon of scarless healing [9]. The 
main collagen in foetal skin contains type I and III collagen. The percentage of type III 
collagen in skin is higher in foetal skin than in adult skin, i.e. 30-60% versus 10-20%, 
respectively [8]. The high content of type III collagen is thought to be an important factor 
for the scarless nature of foetal wound healing [8]. Another component of the ECM 
found in the foetal ECM and less in adult ECM is hyaluronic acid [9,28,29]. Hyaluronic 
acid stimulates fibroblast migration [8], probably resulting is rapid regeneration of the 
damaged dermis in comparison to adult wound healing. 
In addition to the fast migration of fibroblasts, foetal fibroblasts are shown to be 
different in comparison to their adult counterparts. The main difference is the increased 
production of collagen and the percentage of type III and IV collagen produced [8,9]. 
Foetal fibroblasts produce collagen while proliferating [9], possibly via an alternative 
translationatory machinery using IRES sites [30]. In addition, foetal fibroblasts produce 
more hyaluronic acid  and display more receptors for hyaluronic acid [9]. The fibroblasts 
important for adult wound healing are myofibroblasts, which have a role in wound 
closure by contraction and production of collagen. The produced collagen is laid down in 
a parallel pattern resulting in a scar. In wounds made in early gestation, myofibroblasts 
were almost absent [9].
In mammals the ability to heal without a scar is age-dependent [9]. In human embryos 
scarring can be observed after 24 weeks of gestation and in mice after 18.5 days post 
conception [9]. Within the transition period between scarless healing and healing with a 
scar, the size of the wound determines the outcome of wound healing [9].
1.2.3 Wound types
In this thesis, we focus on the development of a tissue engineered construct for burn 
wounds [31,32]. Burn wound healing is essentially the same as normal wound healing, 
although the degree of systemic inflammation is more pronounced [31]. Burn wounds 
can be classified on the depth of the wound. In first degree burns only the epidermis 
is damaged, while in second degree burns the epidermis and part of the dermis are 
affected. First and second degree wounds heal within 2 to 3 weeks, optionally facilitated 
by local wound care, and the damaged tissue is fully regenerated [32].
Full-thickness burn wounds are classified as third or higher degree wounds, depending 
on the number of tissues affected underneath the skin [32]. Large second degree, third 
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9Figure 4 – The 8 stages of hair follicle development according to Paus et al. [14]. Hair 
follicle development start after an interplay in stage 0 between epidermal and dermal 
cells forming a dermal papilla (DP) in stage 1. The dermal papilla will move downward 
and will form a hair germ in stage 2, which will develop into a hair peg in stage 3. In 
stage 4 the inner cell layers of the hair peg differentiate into the inner root sheath cone 
(IRS cone) and the dermal papilla becomes enclosed in the bulb region. Specific hair 
follicle structures start to develop at stage five (5), in which a the bulge area and a 
sebaceous gland become apparent. The first growing hair becomes visible in stage six 
(6) in the formed hair shaft. Stage seven (7) hairs can be found hidden in the hair shafts, 
which become visible in stage eight (8) after birth when hairs emerge out of the skin 
[14]. For a more detailed figure of hair follicle development the reader is referred to the 
original publication by Paus et al. [14]. 
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and higher degree burn wounds are treated by excision of the damaged tissue and 
grafting using an autologous split-thickness skin graft [31]. If the patients do not have a 
suitable donor site for the split-thickness skin graft, an allograft or xenograft is used to 
temporarily cover the damaged skin area [31,33]. The temporary cover can be removed 
when a suitable skin graft or tissue engineered skin construct is placed.
1.3 Skin tissue engineering
Constructs for the treatment of full-thickness wounds can be made from natural or 
synthetic materials and aim to mimick normal skin anatomy, thereby stimulating 
regeneration [34–36]. The design and function of the constructs, however, needs to 
be improved. In essence a functional skin construct should control fluid loss, prevent 
or reduce infection, reduce contraction and reduce scarring [36]. Some examples of 
building blocks for scaffolds will be given. In addition, tissue engineered skin constructs 
used in the clinic or under development will be discussed.
Figure 5 – Stages of wound repair 
(adapted from Gurtner et al. (2008) [15]).
Wound healing can be characterized 
by four stages, i.e. haemostasis (a), 
inflammation (a), proliferation (b) and 
remodelling (c). In the first stage, 
haemostasis (a), a fibrin clot is formed 
as a provisional matrix and a reservoir of 
signalling molecules. In the inflammation 
stage (a), death tissue is removed and 
infection reduced by inflammatory cells. 
In the third stage, proliferation (b), new 
tissue formation is started by migration 
of epidermal cells over the injured dermis 
and subsequent terminal differentiation of 
the newly formed epidermal barrier. The 
formed fibrin clot is replaced by granulation 
tissue in the dermis accompanied by the 
formation of new blood vessels. In the final 
stage of wound healing (c), remodelling 
of the extracellular matrix restores skin 
integrity. 
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For many years the gold standard for the treatment of full thickness wounds has been 
an autologous split-thickness skin graft [37]. A split skin graft, i.e. epidermis with a thin 
layer of dermis, is taken from a donor site on the same patient and transplanted to the 
wounded area. A split skin graft may be combined with a dermal substitute, e.g. the 
combination of an Integra dermal substitute and a split skin graft [38,39]. The main 
advantage of a split skin graft is a high percentage of graft acceptance. The main 
disadvantages of this method, however, are the formation of scar tissue and wound 
contraction [40]. Tissue engineered constructs may offer a better alternative to reduce 
scar tissue and wound contraction by the addition of specific effector molecules.
Three types of tissue engineered skin substitutes exist, i.e. epidermal substitues, dermal 
substitutes and full-thickness skin substitutes [31]. Epidermal substitutes consist of 
cultured epidermal cells, but lack dermal components. Dermal substitues are generally 
acellular matrices [31], although examples with cells exist, e.g. denovoderm [41]. A 
full-thickness skin substitute replaces both epidermis and dermis. In general, tissue-
engineered skin constructs contain three elements, i.e. cells, a scaffold mimicking skin 
ECM and signalling molecules [36]. The scaffold that will be designed in this thesis will 
be acellular, so we will focus mainly on the scaffold and signalling molecules (Figure 5). 
Acellular constructs are designed to simulate the natural ECM and are based on either 
natural materials, e.g. collagen and glycosaminoglycans, or synthetic materials, e.g. 
silicone, polyvinylalcohol and polylactide [36]. The major benefit for natural materials is 
biocompatibility, while synthetic materials tend to have better handling [36]. In Kamel 
et al. (2013) [36] an overview is given of skin constructs used in the clinic and under 
development.
1.3.1 Collagen
Type I collagen is a widely used material as the basic material for natural-based skin 
tissue engineering due to its biocompatibility, low antigenicity, biodegradability and 
availability [34,36,42–45]. It is a member of a large family of more than 28 different 
collagens [46]. As normal skin consists mainly of type I collagen, a type I collagen-based 
construct is probably suitable to mimic the ECM during tissue engineered aided wound 
closure [1]. For the design of an embryonic-like collagen-scaffold, however, it may 
be essential to incorporate type III collagen, since it has been shown that embryonic 
skin contains a higher percentage of this collagen compared to adult skin. Isolation of 
type III collagen is not possible as for type I collagen [47]. There are reports, however, 
that suggest that type III collagen can be produced in the yeast Pichia pastoris [48].
The higher percentage of type III collagen is thought to be an important factor for the 
scarless nature of foetal wound healing [8]. 
1.3.2 Glycosaminoglycans in skin constructs
Glycosaminoglycans (GAGs) are added to a tissue engineered construct as they 
regulate signalling molecules [8,34,49] and increase the water-binding capacity [50]. 
The molecules can be attached to the tissue engineered construct via crosslinking [51]. 
In section 1.4 an overview is given on glycosaminoglycans. This section will focus on 
examples of glycosaminoglycans in tissue engineering.
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Heparan sulfate (HS) is known for its interaction with signalling molecules and its 
specific modifications, may regulate tissue specific growth factor binding and release 
[52–55]. In this research project heparin will be incorporated into the scaffold as 
described in earlier publications of our research group [56]. Chondroitin sulfate has 
been used for incorporation into tissue engineered constructs as well [51]. An example 
of a commercially available skin construct, containing shark chondroitin sulfate, is 
Integra® [57].
Hyaluronic acid, a non-sulfated GAG, has been reported to be present in the embryonic 
ECM [9,28,29], and therefore it is of interest for the aim of this research project, i.e. 
mimicking embryonic development in a skin construct. Hyaluronic acid is used in 
commercially available constructs such as Laserskin®, Hyalomatrix® and Hyalograft® 
[36]. 
1.3.3 Effector molecules 
A tissue engineered construct can be combined with effector molecules, like growth 
factors, morphogens, cytokines and other cells signalling molecules. The effector 
molecules trigger cellular responses of cells transplanted with the construct or cells 
migrating into the construct. Depending on the aim of the treatment, the signalling 
molecules incorporated into the construct can promote migration, proliferation or 
differentiation. In case of a temporary construct, used to protect the wounded area, one 
can postulate on the addition of anti-inflammatory effector molecules [36]. 
Based on studies done on the transforming growth factor beta family (TGFβ), it was 
proposed that addition of TGFβ isoform 3 (TGFβ3) could lead to scarless healing in 
an adult wound [16]. This was based on the observation that the effector molecule 
profile in foetal wound healing showed increased levels of TGFβ3 and decreased levels 
of platelet-derived growth factors, TGFβ1 and TGFβ2 [58]. Experiments using TGFβ3, 
however, did not result in scarless healing [59].
Another growth factor family with a possible role in scarless healing is the fibroblast 
growth factor (FGF) family, which is a large family of 21 isoforms involved in various 
cellular processes. Within this family FGF2, FGF7 and FGF10 are suggested to be 
important for adult wound healing [36]. It has been shown that during scarless wound 
healing FGF2 is important as well [60], while FGF7 and FGF10 are downregulated [61].
1.4 Glycosaminoglycan synthesis and 
degradation
Glycosaminoglycans (GAGs) have been shown to be important for normal development, 
since it has been suggested that glycosaminoglycans (GAG), such as heparan sulfate 
(HS), chondroitin sulfate (CS) and dermatan sulfate (DS), play a role in binding, guiding 
and modulating growth factors and morphogens during various cell signaling processes 
[53,62,63] and are involved in the development of the ECM [64,65]. In addition GAGs 
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have been shown to be involved in the formation of effector molecule gradients, 
which are essential for the developmental processes [66–68]. GAGs can be found in 
different structures within skin, e.g. heparan sulfate in the basement membrane [69], 
chondroitin sulfate and dermatan sulfate in the dermis [70] and hyaluronic acid during 
skin development [8].
1.4.1 GAG synthesis
To synthesize GAGs UDP-activated sugar monomers are made including UDP-
acetylglucosamine (UDP-GlcNAc), UDP-acetylgalactosamine (UDP-GalNAc) and UDP-
glucuronic acid (UDP-GlcA). The UDP-activated monomers are transported from the 
cytoplasm to the Golgi system. In the Golgi system proteoglycan are formed consisting 
of a proteoglycan core protein (PG) and one or more sugar chains, i.e. HS, CS and DS 
[71].
1.4.2 Proteoglycans and the linkage region
Proteoglycan (PG) core proteins display GAGs and are classified on the type of sugar 
chain attached, i.e. HSPG, CSPG or DSPG for HS, CS and DS, respectively. The sugar 
chain is bound to specific serine residues on the core protein via a linkage region [72]. 
The linkage region is formed by the addition of a xylose sugar (Xyl) to the serine residue, 
followed by the addition of two galactose (Gal) and one glucuronic acid residue (GlcA) 
[72].
1.4.3 Initiation and elongation
The subsequent sugar added to the linkage region determines if the sugar chain will 
be a HS chain or a CS/DS chain. Addition of N-acetylglucosamine (GlcNAc) to the 
linker region will initiate the synthesis of heparan sulfate (HS) and the sugar chain is 
elongated by alternating addition of GlcA and GlcNAc monomers (Figure 6) [53,72]. 
CS and DS chains are initiated by the addition of N-acetylgalactosamine (GalNAc) and 
elongated by alternating addition of GlcA and GalNAc monomers [72].
1.4.4 Modification
The HS and CS/DS chain will be further processed in the Golgi system during and after 
polymerization by modifications of the individual saccharide units. The modification of 
HS can be described in several steps (Figure 6). The first step is the N-deacetylation 
and N-sulfation of GlcNAc residues by N-acetylglucosaminyl-N-deacetylase/N-
sulfotransferases (i.e. Ndst1, 2, 3 and 4). The GlcA residues are epimerized into iduronic 
acid (IdoA) residues by glucuronyl C5 epimerase (Glce). The IdoA residues, and in a 
lesser extent the remaining GlcA residues, are subsequently sulfated at the 2-O position 
by heparan sulfate 2-O sulfotransferase (Hs2st). 
The GlcNS and sporadically the GlcNAc residues are sulfated at the 6-O position by 
three heparan sulfate 6-O sulfotransferases (Hs6st1, 2 and 3) and/or sulfated at the 3-O 
position by seven heparan sulfate 3-O sulfotransferases (Hs3st1, 2, 3A, 3B, 4, 5 and 
6). After secretion the modifications continue by the action of two sulfatases (Sulf1 and 
2) aided by their cofactors (sulfate-modifying factor 1 and 2) which specifically remove 
14
Figure 6 – Heparan sulfate synthesis. After initation of heparan sulfate (HS) synthesis by 
the addition of N-acetlylated-glucosamine (GlcNAc) to the xylose-galactose-galactose-
glucuronic acid (Xyl-Gal-Gal-GlcA) linker region, the chain is elongated. GlcNAc units 
can be deacetylated and N-sulfated. Subsequently the GlcA units can be epimerized 
into iduronic acid (IdoA) units and sulphated at the 2-O position. The GlcNS units can be 
sulphated at the 6-O and 3-O position. This figure is adapted from Poulain and Yost [80].
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sulfate groups at the 6-O position of the GlcNS and GlcNAc residues [53,73,74].
The CS and DS chain can be modified at the 2-O and 3-O position of the GlcA unit and 
at the 4-O and 6-O positon of the GalNAc unit [75]. The main difference between CS 
and DS is, that DS contains epimerized GlcA units [72].
1.4.5 GAG degradation
Glycosaminoglycan chains are generally degraded in smaller sugar polymers outside 
the cell, internalized via endocytosis and subsequently processed to monomeric sugar 
units in lysosomes. The sugar monomers can be recycled to form new sugar chains [72]. 
Heparanase is an enzyme important for HS degradation that is also involved in wound 
healing, as overexpression of heparanase resulted in accelerated wound healing [76].
1.5 Aims and outline of the research
The major aims of the PhD project were: 1) construction and evaluation of type I 
collagen based constructs crosslinked with glycosaminoglycans and loaded with 
effector molecules to mimic embryonic scaffolds,  and 2) the study of glycosaminoglycan 
metabolism during skin formation. 
In  Chapter 2, an overview is given of gene expression analysis of embryonic skin based 
on EXON array data, resulting in a selection of twenty growth factors. Two of these 
growth factors, i.e. insulin-like growth factor 2 and sonic hedgehog, were incorporated 
into a type I collagen-heparin construct. In addition, Chapter 2 also describes the 
creation of type I collagen-hyaluronan scaffolds.
Chapter 3 presents a new method to analyse the outcome of collagen construct treated 
wounds, where newly synthesized collagen can be discriminated from the collagen in 
the construct. This method is based on the detection of dermatan sulfate with the single-
chain antibody GD3A12 [77]. 
In Chapter 4 research is presented towards the development of an effector molecule 
gradient. The approach described uses a gradient of glycosaminoglycans, which 
resulted in a gradient of the effector molecule fibroblast growth factor 2. 
In Chapter 5 the role of glycosaminoglycans in skin is discussed based on a gene 
expression study using EXON arrays and custom designed taqman low density 
arrays (TLDA cards). In addition the expression in two mouse models is analysed, 
i.e. an glucuronic acid epimerase knockout mouse model [78] and a heparanase 
overexpression model [79]. 
Chapter 6 focusses on another organ (lung) and describes that a lack of heparan 
sulfate/overexpression of heparanase  is associated with destruction of lung tissue. 
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Abstract
Autologous skin grafts are the gold standard for the treatment of burn wounds. In a 
number of cases, treatment with autologous tissue is not possible and skin substitutes 
are used. The outcome, however, is not optimal and improvements are needed. Inspired 
by scarless healing in early embryonic development, we here set out a strategy for 
the design and construction of embryonic-like scaffolds for skin tissue engineering. 
This strategy may serve as a general approach in the construction of embryonic-like 
scaffolds for other tissues/organs. As a first step, key effector molecules upregulated 
during embryonic and neonatal skin formation were identified using a comparative gene 
expressing analysis. A set of 20 effector molecules was identified, from which insulin-
like growth factor 2 (IGF2) and sonic hedgehog (SHH) were selected for incorporation 
into a type I collagen–heparin scaffold. Porous scaffolds were constructed using purified 
collagen fibrils and 6% covalently bound heparin (to bind and protect the growth factors), 
and IGF2 and SHH were incorporated either individually (~0.7 and 0.4 μg/mg scaffolds) 
or in combination (combined ~1.5 μg/mg scaffolds). In addition, scaffolds containing 
hyaluronan (up to 20 μg/mg scaffold) were prepared, based on the up- or downregulation 
of genes involved in hyaluronan synthesis/degradation and its suggested role in scarless 
healing. In conclusion, based on a comprehensive gene expression analysis, a set of 
effector molecules and matrix molecules was identified and incorporated into porous 
scaffolds. The scaffolds thus prepared may create an ’embryonic-like’ environment for 
cells to recapitulate embryonic events and for new tissues/organs.
Chapter 2
25
Introduction
Third-degree and chronic wounds covering large areas need to be treated to aid the 
natural process of wound healing. Full- and split-thickness skin grafts are the golden 
standards. Treatment with a full-thickness skin graft will lead to maximal functionality 
and minimal scar formation. Treatment with meshed split-thickness skin grafts, however, 
may result in scar formation, since the graft is meshed to cover a larger wound area and 
contains only part of the dermis in comparison to full-thickness skin grafts (Adams and 
Ramsey, 2005). Both treatments create a secondary wound at the donor site, which is 
limited in patients with large burn wounds. In addition, both treatments are generally 
not used for patients with vascular disease (Adams and Ramsey, 2005; Metcalfe and 
Ferguson, 2007; Wood and Davies, 1995). Tissue engineered skin grafts offer an 
alternative in such cases (Macri and Clark, 2009). Different types of skin grafts are 
commercially available, including those based on decellularized cadaveric skin (e.g. 
Alloderm), those based on natural materials, such as type I collagen (e.g. Apligraf and 
Integra) and those based on synthetic materials (e.g. Dermagraft). Constructs are 
either acellular (Alloderm and Integra) or cellular (Apligraf and Dermagraft) (Supp and 
Boyce, 2005; van der Veen et al., 2010). The current skin grafts all have their own 
advantages and disadvantages but share common problems, such as poor graft take 
due to inadequate vascularization, scarring due to improper collagen deposition and 
reduced functionality due to lack of appendages (Metcalfe and Ferguson, 2007). Most 
importantly, the outcome of tissue-engineered skin grafts is generally worse than that of 
full- or split-thickness skin grafts (Gurtner et al., 2008), and improvements are needed. 
In this study, we take an alternative approach to constructing skin grafts, emanating 
from processes taking place during embryonic skin development.
It has long been known that embryonic wounds can heal without the formation of scar 
tissue (Bullard et al., 2003), depending on the gestational age and size of the wound. The 
major differences of early embryonic scarless healing in comparison to late embryonic/
adult scar healing are the lack of a fibrin clot, a reduced inflammatory response and 
elevated levels of effector molecules (growth factors/morphogens) important for skin 
morphogenesis (Bullard et al., 2003; Metcalfe and Ferguson, 2007). In addition, the 
extracellular matrix depositions of early embryonic dermal fibroblasts and late embryonic/
adult fibroblasts differ (Metcalfe and Ferguson, 2007). Addition of embryonic effector 
molecules and extracellular matrix components may induce embryonic-like processes 
leading to better wound healing, such as less contraction, less scar tissue formation, 
improved mechanical properties and regeneration of appendages. Mouse skin is formed 
from endoderm and mesoderm 7.5–17.5 days postconception (E7.5–E17.5). After birth, 
skin matures further, e.g. by the outgrowth of hairs (Rossant and Tam, 2002). Several 
effector molecules have been reported to be important for embryonic skin development, 
including members of the wingless-type MMTV integration site (WNT) family, the 
transforming growth factor (TGF) family, the fibroblast growth factor (FGF) family and 
the epidermal growth factor (EGF) family (McElwee and Hoffmann, 2000). 
In this study we set out a design strategy to identify (effector) molecules associated with 
skin embryonic processes, and construct scaffolds containing such molecules, thereby 
creating an ’embryonic-like’ microenvironment. The methodology may be adopted for 
the construction of embryonic-like scaffolds for other tissue/organs.
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Figure 1. General design for the construction of embryonic-like scaffolds. Time points 
were selected, based on the literature, of important events during embryonic skin 
development. The picture shows an E14 embryo (A). At the selected time points, 
E14, E16, P1 and P90, mRNA of mouse skin was isolated and used for expression 
analysis with GeneChip exon arrays (B). Data were screened for differential expression 
of effector molecules (growth factors/morphogens). The expression of the selected 
molecules was validated using real-time quantitative PCR and immunohistochemistry 
(C); E16 skin stained for IGF2 (white dotted line depicts the basal membrane separating 
the epidermis and dermis). Selected effector molecules were incorporated into a type 
I collagen–heparin scaffold (D); SEM image of collagen scaffold with heparin (yellow 
lines) and effector molecules (blue spheres) schematically shown.
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Materials and methods
An overview of the experimental set-up of this study is given in Figure 1.
Animals
NIH guidelines for the care and use of laboratory animals (NIH publication 85–23 Rev. 
1985) were observed. The study was approved by the Ethics Committee of the Radboud 
University Nijmegen. C57BL6/j mice were obtained from Elevage Janvier (Le Genest 
Saint Isle, France). Mice 90 days of age (90 days post birth [P90]) were used for timed 
matings and embryos were isolated at 14 days post conception (E14), 16 days post 
conception (E16), and 1 day post birth (P1).
RNA isolation
For E14, skin from seven embryos (one litter) was pooled for RNA isolation. For E16, 
two litters of seven embryos were used for two samples (each sample from a separate 
litter). For P1, two litters of three pups were used for two samples (each sample from 
a separate litter). For P90, two individual mice were used for two samples. Dorsal-
lateral skin was snap-frozen in liquid nitrogen and stored at -80o C. For the E14 
embryos, dorsal–lateral skin was scraped using a cryomicrotome at -20o C to minimize 
contamination with other tissues, which was checked by haematoxylin and eosin (H&E) 
staining (Bancroft and Stoeltzing, 1990) (results not shown). The frozen samples were 
ground in a microdismembrator (Sartorius, Bunnik, The Netherlands) and RNA was 
isolated using the TRIZOL method (Invitrogen, Paisley, UK) in combination with RNeasy 
Mini kit with DNAse step (Qiagen, Hilden, Germany). RNA quality was checked using 
the Bioanalyser system (Agilent Technologies, Amstelveen, The Netherlands). The RNA 
integrity numbers and the rRNA ratios (see Supporting information, Table S1) were 
sufficient for gene expression analysis, based on criteria described by Schroeder et al. 
(2006).
GeneChip mouse exon 1.0 ST array
GeneChip Mouse Exon 1.0 ST arrays (exon arrays; Affymetrix, High Wycombe, UK) 
were used to analyse expression, using 1 μg RNA/chip. The quality of the expression 
data was checked based on Kadota et al. (2009) (see Supporting information, Table 
S1). Gene level expression data were calculated for the CORE transcripts (probe sets 
supported by RefSeq mRNAs), using Affymetrix Expression Console software with 
quantile normalization (all arrays are considered to have an equal intensity distribution), 
GC content background correction (probes with high GC content hybridize better, 
corrected for with built-in probes with different known GC contents) and summarization 
with the RMA algorithm (Lammers et al., 2010). Data were imported into GeneSpring 
GX 7.3 (Agilent Technologies), duplicates were averaged and the expression of each 
transcript was normalized to the median per array. Statistical significance was tested 
using ANOVA and Benjamini-Hochberg multiple testing correction (Benjamini and 
Hochberg, 1995).
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cDNA synthesis and real-time quantitative PCR (qPCR)
cDNA was made from RNA samples using the Superscript III First-Strand Synthesis system 
(Invitrogen) with random hexamers. cDNA was tested by conventional PCR (Fast start Taq 
polymerase, Roche, Almere, The Netherlands), using primers against GAPDH (forward 
5`- TGATGGGTGTGAACCACGAG-3`, reverse 5`-GGGCCATCCACAGTCTTCTG-3`). 
The 7000 Sequence Detection System (Applied Biosystems, Warrington, UK) and the 
Power SYBR Green PCR Master Mix from Applied Biosystems were used for Real-time 
quantitative PCR (qPCR) validation with custom-designed primers (for IGF2, forward 
5`-TGTGCTGCATCGCTGCTTAC-3`, reverse 5`-CGGCCTGAGAGGTAGACACG-3`; 
for SHH, forward 5`-GCGGCAGATATGAAGGGAAG-3`, reverse 
5`-CTCCAGGCCACTGGTTCATC-3`). Primers (Isogen Bioscience, Maarssen, The 
Netherlands) were tested for qPCR usage based on the slope and linear regression of 
a standard curve (Wong and Medrano, 2005).
Expression was analysed based on the threshold cycle (CT), which was obtained using 
SDS 2.3 software and RQ Manager 1.2 (Applied Biosystems). The CT values were 
further processed using Microsoft Excel and the 2–ΔΔCT method, using GAPDH as the 
reference gene and P90 as the calibrator point (Livak and Schmittgen, 2001). Statistical 
significance was tested with an unpaired t-test (two-tailed) using SPSS 18.0 (SPSS/
IBM, Chicago, IL, USA).
Immunohistology
For paraffin sections, specimens were fixed in 4% paraformaldehyde in 0.1M phosphate 
buffer (PB), pH 7.4 (Sigma-Aldrich, Zwijndrecht, The Netherlands), for 4 h, stored in 
70% ethanol (Royal Nedalco, Bergen op Zoom, The Netherlands) and subsequently 
embedded in paraffin. Paraffin sections (5 μm) were stained with H&E (Bancroft and 
Stoeltzing, 1990). For immunohistochemistry, sections were deparaffinized, hydrated 
and treated for antigen retrieval, using 0.1% trypsin (DIFCO Laboratories, Detroit, 
USA) for 15min at 37 oC (0.1% trypsin containing 0.1% calcium chloride, pH 7.4) and 
subsequently in 0.01M sodium citrate buffer, pH 6.0, for 2 h at room temperature.
For cryo-sections, samples were snap-frozen in liquid nitrogen-cooled isopentane 
(Sigma-Aldrich, Zwijndrecht, The Netherlands); 4 μm sections were cut, mounted 
on Superfrost slides (Menzel-Gläser, Braunschweig, Germany) and air-dried. Before 
staining, the sections were fixed for 10 min in 4% paraformaldehyde. The sections were 
blocked with phosphate-buffered saline (PBS) containing 1% bovine serum albumin 
(BSA) and 0.1% Tween (PBS–T–BSA), incubated with primary antibodies in PBS–T–
BSA (Table 1) and subsequently with the appropriate secondary and tertiary antibodies. 
After a short dehydration step with 100% ethanol, the sections were embedded in 
MOWIOL (Calbiochem, Darmstadt, Germany).
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Scaffold preparation and analysis
Collagen–heparin scaffolds
Collagen scaffolds were prepared from type I collagen fibrils isolated from bovine 
Achilles tendon (Pieper et al., 1999) and prepared by freezing and lyophilizing a 0.8% 
suspension in 0.25 M acetic acid (Merck) at -20o C (Pieper et al., 2002). Scaffolds were 
crosslinked with 0.05% heparin in the crosslinking solution [33mM 1-ethyl-3-dimethyl 
aminopropyl carbodiimide (EDC) and 6mM N-hydroxysuccinimide (NHS) in 50mM 
2-morpholinoethane sulphonic acid, pH 5.0, containing 40% ethanol (Merck)]. The 
crosslinking reaction was stopped by washings in 0.1M Na2HPO4, 1M NaCl, 2M NaCl 
and demineralized water. The scaffolds were frozen at -80o C using dry-ice/ethanol and 
lyophilized. The scaffolds used in the experiment were approximately 1mg.
Collagen–heparin–effector molecule(s) scaffolds
To incorporate the effector molecules, collagen–heparin scaffolds were incubated in 
200 μl PBS containing 20 μg/ml carrier-free mouse recombinant IGF2 (792-MG, R&D 
Systems, Oxon, UK) and/or 10 μg/ml carrier-free mouse recombinant SHH (461-SH/CF, 
R&D Systems) per mg scaffold for 1 h at room temperature. The scaffolds were washed 
once with PBS and twice with demineralized water for 15 min.
The morphology of the scaffolds was analysed using scanning electron microscopy 
(SEM), using a JEOL JSM-6310 SEM at 15 kV (Daamen et al., 2005). The degree 
of crosslinking was analysed using 2,4,6-trinitrobenzene sulphonic acid (TNBS) (Olde 
Damink et al., 1996) and the amount of bound heparin using a hexosamine assay (Pieper 
et al., 1999). The amount of bound growth factor was analysed using western blotting with 
antibodies against SHH (1:5000) and against IGF2 (1:500) (Table 1), using peroxidase-
conjugated secondary antibodies and visualization using a chemiluminescent detection 
kit (ECL Kit, GE Healthcare, Diegem, Belgium) (Nillesen et al., 2007). The amount of 
bound growth factor was determined in triplicate, based on a standard curve present 
on the gel.
Collagen–hyaluronan scaffolds
0.0125%, 0.025% or 0.05% hyaluronic acid sodium salt (Fluka, MW 1.63 x 103 kDa) was 
suspended in 0.25M acetic acid and type I collagen fibrils were added. The suspension 
was mixed and was allowed to swell overnight at 4 oC. The swollen suspension was 
homogenized and lyophilized. Scaffolds were crosslinked as described above. 
The amount of bound hyaluronan was analysed using a modified Stains-All DPTC 
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(4,5,4`5`-dibenzo-3,3`-diethyl-9-methyl-thiacarbocyanine; Sigma) colorimetric assay 
(Edstrom, 1969). The scaffolds were digested for 1 h in a papain solution (2.5 U/ml; 
Sigma) in phosphate buffer (50mM Na3PO4, 2mM EDTA, 2mM cysteine, pH 6.5). For 
the calibration curve, 100 μl standards were used containing 0–5 μg hyaluronic acid 
sodium salt. To 100 μl of the digested scaffolds, 900 μl staining solution was added 
[2.8 mg Stains-all in 5ml 50% isopropanol (Merck), 42.5ml demineralized water, 100 
ml 1M acetic acid (Merck) and 2.5 ml 0.01M ascorbic acid (Sigma)]. Hyaluronan 
contentwas measured at 650 nm. For immunohistochemistry, paraffin sections were 
used. Specimens were fixed and stored in Kryofix [48% ethanol (Royal Nedalco) and 
7%PEG300 (Sigma)] and embedded in paraffin before use. Paraffin sections (5μm) 
were stained as described under histochemistry, but without the antigen retrieval step.
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Results
Histology of developing mouse skin
Embryonic skin development was studied at four time points. At E14 the epidermis 
of dorsal-lateral skin was only a few cell layers thick, the dermis consisting of loosely 
organized cells (Figure 2A). Literature data indicate that hair follicle development is 
initiated at E14 by the formation of a dermal condensation (Rossant and Tam, 2002), 
out of which appendages are formed at E16. Appendages were found at E16 in addition 
to stratification of the epidermis and an organized dermis (Figure 2B). Skin at 1 day 
post-birth (P1) is more organized than at E16 (Figure 2C) and resembles adult skin at 
P90 (Figure 2D).
Selection of effector molecules
Gene expression was analysed using GeneChip Mouse Exon 1.0 ST arrays (Affymetrix). 
The expression data were screened for key effector molecules in embryonic skin 
development, using several selection steps. In the first step of the screening, we 
selected genes that showed significant two-fold differential expression (p<0.05; 
ANOVA) (see Supporting information, Table S2). In the second step, the resulting 
list was screened for effector molecules which were upregulated during embryonic 
Figure 2. H&E (A–D) and immunohistochemical stainings (E–H) of various stages of 
mouse skin development. (A) At E14 the epidermis (e) is 2–5 cell layers thick and the 
dermis (d) consists of undifferentiated mesenchymal cells and dermal fibroblasts. (B) 
Appendages, e.g. hair follicles (hf), are clearly visible at E16. Epidermis and dermis 
development is well under way. (C) One day post-birth (P1), the skin is stratified and 
hair growth has started. (D) Adult P90 skin; a sebaceous gland is shown (sg). (E–H) 
Cellular staining of IGF2 was seen at E14 and E16. At P1 and P90 staining is decreased 
in comparison to the other time points. Scale bar=50 μm
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development. These molecules, e.g. growth factors and 
morphogens, were identified on the basis of their assigned 
function (growth factor, morphogen, mitogen), as available 
in the Gene database of NCBI (www.ncbi.nlm.nih. gov) and 
the database of Ensembl (www.ensembl.org). In the third 
and last step, the expression data of the effector molecules 
was studied for upregulation at the embryonic and/or early 
postnatal time points (E14, E16 and/or P1) in comparison 
to P90. 
The search resulted in a list of 20 growth factors (Table 2) 
significantly upregulated (p<0.05; ANOVA) at one or more 
of the time points in comparison to P90. Additional statistical 
validation of the results using Benjamini–Hochberg 
multiple testing correction (Benjamini and Hochberg,1995), 
shortened the list to 13 growth factors. It was decided to 
keep the seven genes in the selection, since literature data 
suggested an important role in embryonic development 
(Bayle et al., 2008; Kalinina et al., 2009; Kettunen et al., 2006; 
Nanba et al., 2003; Tao et al., 2002; Wang and Shackleford, 
1996; Woods et al., 2006). From the list of 20, two growth 
factors were selected for incorporation into scaffolds, IGF2 
and SHH. IGF2 was>50-fold upregulated during embryonic 
development (E14 and E16) and at P1. These results were 
validated by real-time qPCR and immunohistochemistry. 
Validation of IGF2 expression by qPCR confirmed the data 
observed with the exon array (e.g. fold change E16 vs P90: 
342 ± 47, p<0.05). Immunohistochemistry showed a strong 
staining of IGF2 at E14 and E16 both in the dermis and 
epidermis (Figure 2E–H). Staining at P1, however, was less 
intense and more comparable to staining at P90. These 
results suggested that IGF2 protein is primarily present 
in the embryonic stages, despite the high level of mRNA 
expression at P1 in the microarray. 
SHH was selected because, next to IGF2, its mRNA was 
upregulated when comparing neonatal to adult skin (about 
4.6-fold at P1; Table 2), which was confirmed by qPCR 
(fold change P1 vs P90: 6.4 ± 2.5, p<0.05). SHH plays a 
prominent role in appendage development (St-Jacques et 
al., 1998). In addition, it is a heparin-binding protein (Zhang 
et al., 2007). Several attempts were made to stain SHH 
using tissue sections, but were unsuccessful. 
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Figure 3. Scaffold structure and distribution of heparin, IGF2, SHH and hyaluronan in 
the prepared embryonic-like scaffolds. (A–C) SEM images show the porous structure of 
type I collagen–heparin scaffolds. (D–G) Staining of heparin was found in the scaffold 
crosslinked with heparin. (H–K) IGF2 and (L–O) SHH staining was found in the scaffold 
loaded with one or both of the growth factors. (P–S) Hyaluronan staining showed it 
was successfully incorporated using a concentration of 0.0250% (Col–Ha-0.0250, Q) or 
0.0500% (Col–Ha-0.0500, R). Hyaluronan staining was not observed in the control (CX, 
P; note that the control shows yellow background staining). Scale bar=100 μm (A–O); 
50 μm (P–R)
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Preparation and evaluation of 
embryoniclike scaffolds
Scaffolds containing effector molecules
To study the possibility of incorporation of the growth factors 
into collagen constructs, we made type I collagen–heparin 
scaffolds and loaded them with IGF2 and SHH. Heparin 
was added because it binds growth factors (e.g. SHH), and 
may promote their sustained release (Geutjes et al., 2006). 
Sonic hedgehog was added to the scaffolds since it was 
significantly upregulated at P1 vs P90 (ANOVA analysis), 
plays a crucial role in development, and because of its 
favourable heparin-binding properties (Nanba et al., 2003; 
St-Jacques et al., 1998; Zhang et al., 2007). Type I collagen 
is used in our scaffold design since it is the main collagen in 
skin (Rossant and Tam, 2002) and shows various favourable 
properties for scaffold design, e.g. low immunogenicity and 
good handling (Geutjes et al., 2006; Pieper et al., 1999).
Type I collagen scaffolds were crosslinked with an EDC/
NHS solution in the presence of 0.05% heparin, resulting 
in 49 ± 1% (mean ± SD, n=3) reduction in primary amine 
groups indicating crosslinking (Table 3). The amount of 
heparin bound to the scaffold was 59 ± 9 μg heparin/mg 
scaffold (mean ± SD, n=3) (Table 3). The incorporation 
of heparin was also evaluated by immunohistochemistry 
(Figure 3D–G). Heparin staining was found predominantly 
at the edges of the scaffold. The scaffolds had a porous 
structure, as visualized using SEM (Figure 3A–C).
The scaffolds were loaded with IGF2 and SHH. Growth 
factor incorporation was studied by western blotting and 
immunohistochemistry. A collagen–heparin crosslinked 
scaffold loaded with IGF2 (Col–Hep–IGF2) contained 0.7 ± 
0.2 μg IGF2/mg scaffold (mean ± SD, n=3). Loading of SHH 
(Col–Hep–SHH) resulted in 0.4 ± 0.1 μg SHH/mg scaffold. 
A scaffold loaded with both growth factors (Col–Hep–IGF2–
SHH) contained 0.8 ± 0.1 μg IGF2 and 0.7 ± 0.1 μg SHH/mg 
scaffold (Table 3, Figure 4). Results are given as average 
± SD (n=3). Immunohistochemistry was used to visualize 
the distribution of IGF2 and SHH. Both SHH and IGF2 were 
found predominantly at the edge of the scaffold, similar to 
heparin (Figure 3H–O).
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Scaffolds containing hyaluronan
Literature data indicate an increased content of hyaluronate (HA) in embryonic skin 
(Metcalfe and Ferguson, 2007). Trends observed in the gene expression data on 
embryonic skin development are in line with this observation, since hyaluronan synthase 
2 (HAS2) was 2.1-fold upregulated at E14 and the expression of HAS3 was >3.5-fold 
upregulated at E16 and P1. The gene expression for HYAL1 (hyaluronidase, involved 
in breakdown of HA) was 6.5-, 4.5- and 2.5-fold downregulated with respect to P90 at 
E14, E16 and P1, respectively (Table 4). 
Collagen scaffolds with covalently bound hyaluronan were constructed by mixing the 
collagen suspension with hyaluronate, freezing, lyophilization and crosslinking. This 
method is different from the construction of type I collagen–heparin scaffolds, where 
heparin is added to the scaffold during the crosslinking step. Crosslinking resulted in 36 
± 8%, 35 ± 8% and 35 ± 10% (mean ± SD, n=3) of reduction in primary amine groups 
in scaffolds to which 0.0500% (Col–Ha-0.0500), 0.0250% (Col–Ha-0.0250) or 0.0125% 
(Col–Ha-0.0125) of hyaluronan was added, respectively (Table 3). 
The amount of hyaluronan bound to the scaffolds was determined using a modified 
Stains-All colorimetric assay (Edstrom, 1969). The scaffolds contained 20 ± 8, 13 ± 
4 and 8 ± 3 μg (mean ± SD, n=3) of hyaluronan/mg scaffold for Col–Ha-0.0500, Col–
Ha-0.0250 and Col–Ha-0.0125, respectively (Table 3). Immunohistochemistry showed 
that hyaluronan was distributed throughout the scaffold (Figure 3P–R). The scaffold 
morphology was similar to that observed for collagen–heparin scaffolds (data not 
shown).
Figure 4. Growth factors bound to scaffolds analysed by western blot. SHH bound to 
the collagen–heparin scaffold is shown in blot A and SHH bound in combination with 
IGF2 is shown in blot B. In blots C andD, IGF2 bound to the collagen–heparin scaffold 
is shown without or in combination with SHH. Three separate growth factor incubations 
were analysed (samples 1–3). Based on the calibration curve, the amount of growth 
factor is estimated and corrected for the volume used and the amount of scaffold in the 
initial sample.
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Discussion
In this study we laid down a general strategy to construct embryonic-like skin constructs 
as an alternative to current skin grafts. It is our hypothesis that incorporation of effector 
molecules, upregulated in embryonic skin development, can stimulate embryonic-like 
processes in the adult wound and may ultimately lead to better skin regeneration, e.g. 
without contraction or scar formation (Metcalfe and Ferguson, 2007). 
Selection of effector molecules
Using high-density gene expression arrays, 20 candidate effector molecules were 
found upregulated during skin development. Six of them have been reported to play 
an important role in skin development, underscoring the validity of the selection 
procedure used here. FGF10 and IGF2 are involved in epidermal development (Bennett 
et al., 2003; Tao et al., 2002) and platelet-derived growth factor-a (PDGFa) in dermal 
development (Betsholtz et al., 2001). WNT10b and SHH have been reported to regulate 
appendage formation, e.g. hair follicles (Nanba et al., 2003; Ouji et al., 2008). TGFb3 
is expressed in the epidermis, dermis and hair follicles during skin development, but its 
specific function remains to be elucidated (Pelton et al., 1991). FGF10 is suggested to 
have a role in the early stages of adult wound healing, since expression is upregulated 
1 day after wounding (Tagashira et al., 1997).
In addition to the six genes with a described/proposed function, we found 14 genes with 
an unknown function in skin development but a reported function in other developmental 
processes. Additional research is needed to elucidate their role during skin development, 
especially because some genes show favourable properties. FGF9, for instance, could 
be involved in dermal and appendage development via stimulation of SHH and FGF10 
(White et al., 2006). Another example is WNT2 and WNT2b, which could have a function 
in dermal development, based on a fibrillin-1 skin fibrosis model in which WNT2 and 
WNT2B are upregulated after an in-frame duplication of the fibrillin-1 gene (Bayle et 
al., 2008). Thus, 14 new effector molecules were identified using the strategy taken, in 
addition to the confirmation of six genes with a known role in skin development. The 
novel effector molecules may be important for the construction of new biomaterials.
Scaffolds containing effector molecules
The basic scaffold for incorporation of effector molecules was based on collagen fibrils 
to which heparin was covalently attached. Heparin binds, protects and modulates a 
large number of effector molecules, including a number of the molecules identified in 
this study, such as FGF9 and FGF20 (Kalinina et al., 2009), FGF10 (Izvolsky et al., 
2003), FGF18 (Chuang et al., 2010), PDGFa (Feyzi et al., 1997), SHH (Zhang et al., 
2007) bone morphogenetic protein 3 (BMP3), BMP5, growth differentiation factor 10 
(GDF10) (Cunningham et al., 1995) and the WNT proteins (Lin 2004). TGFb3 and IGF2, 
however, are reported not to bind to heparin (Arai et al.,1996; Lyon et al.,1997), although 
the latter could be incorporated in a collagen–heparin-based construct.
To test whether it is possible to make an embryonic-like construct, we decided to make 
a collagen–heparin scaffold containing IGF2 and SHH. IGF2 induces proliferation of 
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transient amplifying cells or stem cells in the basal epidermal layer (Bennett et al., 2003) 
and stimulates angiogenesis via VEGF in the dermis (Kim and Kim, 2005). Stimulation 
of angiogenesis may lead to better graft take through faster vascularization (Metcalfe 
and Ferguson, 2007). SHH induces proliferation of cells in both the basal epidermal 
layer and the dermal layer and potentially even induces appendage formation (Nanba 
et al., 2003; St-Jacques et al., 1998; Zhou et al., 2006). Restoring appendages could 
increase the functionality of the repaired/regenerated skin (Metcalfe and Ferguson, 
2007). Both effector molecules could be successfully incorporated in the scaffolds, either 
individually or in combination, and at a concentration high enough to exert a biological 
effect. Although functional testing of the embryonic-like scaffold remains to be carried 
out, we showed that the construction of a scaffold that may induce an embryonic-like 
microenvironment is feasible.
Scaffolds containing specific matrix molecules
Literature data suggested that hyaluronan is an important extracellular matrix component 
during embryonic scarless wound healing (Metcalfe and Ferguson, 2007; Toole, 2001). 
This observation was confirmed by the gene expression data of hyaluronan synthesis-
related genes. Therefore, we decided to incorporate hyaluronan in our scaffolds and 
we were able to create collagen–hyaluronan scaffolds that contained up to 20 μg 
hyaluronan/mg scaffold. Hyaluronan has an important role in late embryonic and adult 
wound healing. It regulates the inflammatory response, organizes the granulation tissue 
matrix and facilitates cell proliferation and migration (Chen and Abatangelo, 1999). 
Based on the role of hyaluronan during embryonic development and embryonic/adult 
wound healing, we suggest that incorporation of hyaluronan into a tissue-engineered 
skin graft may accelerate and improve wound healing. Currently, one hyaluronan-based 
skin graft, Hyalomatrix (Price et al., 2007), is commercially available and is reported to 
promote neodermis formation (Myers et al., 2007). Based on the described effects of 
Hyalomatrix and the properties of hyaluronan, addition of hyaluronan to a type I collagen 
construct may lead to better neodermis formation (Myers et al., 2007) and enhanced cell 
proliferation and migration in the dermal compartment (Chen and Abatangelo, 1999). 
Combined with effector molecules, such a scaffold may recapitulate early events of skin 
generation and thus contribute to proper regeneration of skin tissue.
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Conclusion
In this study we propose a general strategy to design and construct ’embryonic-like’ 
scaffolds targeted to create a microenvironment which may stimulate cells to take 
an embryonic-like approach to regenerate tissues and organs. We have shown the 
feasibility of the identification of effector molecules upregulated during development 
by gene expression microarrays, and of the subsequent construction of scaffolds 
containing such molecules. The approach may be generally applicable for the design of 
embryonic-like scaffolds for other tissues/organs. In vitro/in vivo testing should be the 
next step to evaluate the functionality of the scaffolds. 
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Abstract
Identifying collagen produced de novo by cells in a background of purified collagenous 
biomaterials poses a major problem in for example the evaluation of tissue-engineered 
constructs and cell biological studies to tumor dissemination. We have developed a 
universal strategy to detect and localize newly deposited collagen based on its inherent 
association with dermatan sulfate. The method is applicable irrespective of host species 
and collagen source.
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Introduction
Collagen, the most abundant protein family in the human body, plays a pivotal role in the 
organization of tissues and organs, and is a major determinant during organogenesis. 
In the field of tissue engineering and regenerative medicine, type I collagen is a 
key biomaterial1 whereas in other fields, notably cancer research, collagen gels are 
frequently used in 3D studies to the migrational behavior of cells2.
A common challenge in the field is to make a distinction between the collagen synthesized 
by cells and the (abundant) pre-existing collagen present in the biomaterial. Antibodies 
raised against collagens are of limited use due to the highly conserved nature of 
collagens3 and the associated cross reactivity between collagen from different species. 
Other methods like metabolic radiolabeling and mass spectrometry4 are laborious 
and do not provide information about the topography and organization of the newly 
synthesized collagen fibers.
In this study we evaluated newly synthesized fibrillar collagen (e.g. type I collagen), by 
making use of the inherent and intrinsic association of the glycosaminoglycan dermatan 
sulfate with collagen fibrils. Dermatan sulfate is the glycosaminoglycan part of the 
proteoglycans decorin and biglycan, which are both collagen fibril-associated molecules 
that play a role in the regulation of collagen fibril diameter. These proteoglycans 
remain present on the mature collagen fibril (Fig. 1a, cartoon), and therefore dermatan 
sulfate is associated with collagen fibrils5,6. The technique described here is based on 
the selective detection of dermatan sulfate using the single chain variable fragment 
antibody GD3A127, combined with the absence of dermatan sulfate in experimentally 
or commercially produced biomaterials. We tested the technique both in vivo and in 
vitro using a number of collagenous biomaterials including gels cultured with human 
fibroblasts with or without keratinocytes (denovoSkin and denovoDerm respectively)8, 
experimental and commercially available scaffolds, and glycerol preserved acellular 
human dermis (Glyaderm®)9.
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Figure 1. Overview and validation of strategy to identify newly synthesized collagen by 
dermatan sulfate. (a) Cartoon illustrating the intrinsic association of dermatan sulfate with 
collagen fibrils. (b) Identification of collagen fibrils using the anti-dermatan sulfate single 
chain antibody GD3A12. Arrows indicate immunogold labeling on collagen fibrils (rat 
kidney tissue, Bowman’s capsule), but not on other structures such as cells and basement 
membranes. (c) Specificity of the anti-dermatan sulfate antibody as evidenced by loss 
of immunostaining after digestion of dermatan sulfate by chondroitinase B (rat kidney 
tissue). Note co-localization of dermatan sulfate and type I collagen. (d,e) Absence of 
dermatan sulfate in pre-seeded/pre-implanted collagenous biomaterials as indicated by 
(d) immunostaining for dermatan sulfate (antibody GD3A12), (e) biochemical analysis 
of dermatan sulfate (agarose gel electrophoresis). In (d) arrows indicate identical areas 
stained for dermatan sulfate and type I collagen. In (e), lanes 1–3 represent acellular 
collagen gels/scaffolds, whereas lanes 4 and 5 represent cellularized gels. M, marker 
containing 5 ng each of chondroitin sulfate (CS), dermatan sulfate (DS) and heparan 
sulfate (HS). coll.fibril: collagen fibril.
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Results
To evaluate the potential of the anti-dermatan sulfate antibody to identify collagen 
fibrils we applied immuno-electron microscopy using rat kidney cryosections. Antibody 
reactivity, as visualized by gold sphere-labeled protein A, was confined to collagen fibrils 
whereas other structures like cells and basement membranes did not stain (Fig. 1b). 
Using immunofluorescence, antibody staining for dermatan sulfate was shown to co-
localize with type I collagen, and was abolished by pretreatment of the sections with 
chondroitinase B, which specifically digests dermatan sulfate (Fig. 1c).
Absence of dermatan sulfate in the biomaterials 
All collagenous biomaterials used were tested for the presence of dermatan sulfate, 
using immunohistochemical and/or biochemical techniques. Using immunofluorescence, 
dermatan sulfate could not be detected in any of the biomaterials (Fig. 1d, and 
supplementary Figure S1). In addition, using a highly sensitive silver staining method, 
dermatan sulfate could not be observed in collagen scaffolds (Fig. 1e, lane 1) or in 
collagen gels (Fig. 1e, lane 2 and 3). 
Collagen deposition in vitro and in vivo 
Having demonstrated the capacity of the antibody to detect collagen fibrils by virtue of 
its association with dermatan sulfate, and having established the absence of dermatan 
sulfate in collagenous biomaterials, we studied newly synthesized collagen fibrils 
produced by cells both in vitro and in vivo, using dermatan sulfate staining. Fibroblasts 
cultured in vitro in a collagenous gel produced collagen as evidenced by the presence 
of dermatan sulfate, which co-localized with type I collagen. Use of anti-type I collagen 
antibody did not discriminate between bovine collagen from the scaffold and the human 
collagen produced by the fibroblasts (Fig. 2a1–3). Dermatan sulfate staining, however, 
indicated the location of newly synthesized human collagen and was not present in 
the bovine scaffold collagen. Dermatan sulfate was also identified biochemically, and 
was detected only in cellularized collagen gels, and not in gels without cells (Fig. 1e, 
lane 4). The location of newly synthesized collagen was time dependent, and initially 
present only at the perimeter of the fibroblasts (Fig. 2b1). At later stages (e.g. 12 days 
of culturing) collagen was also located further away from the cells, and eventually most 
of the original gel contained newly synthesized collagen (Fig. 2b4). These results were 
confirmed biochemically, showing increased amounts of dermatan sulfate as a function 
of time (Fig. 1e).
Glycosaminoglycans are evolutionary highly conserved structures that are found 
throughout vertebrates as well as invertebrates10. It may therefore be expected that the 
anti-dermatan sulfate antibody can be used irrespective of the species that deposits the 
collagen. To evaluate this we stained collagen scaffolds implanted in different animal 
species and in humans. The following samples were used: 1) a flat collagen scaffold 
implanted subcutaneously in mice, 2) a tubular collagen scaffold implanted in the ureter 
of pigs, 3) a commercial collagen-chondroitin sulfate skin substitute (Integra®) implanted 
in a full-thickness skin defect in rats11, 4) Integra® implanted in a soft tissue palatal defect 
in dogs12, 5) Glyaderm® (acellular human dermis) implanted in a full-thickness skin defect 
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Figure 2. Detection of newly synthesized collagen fibrils in cellularized/implanted 
collagenous biomaterials. (a) Collagen gel cultured for 6 days with human fibroblasts. 
Newly deposited collagen is indicated by green dermatan sulfate staining (a2,a3), 
whereas all collagen is indicated by red type I collagen staining (a1,a3). (b) Location of 
newly deposited collagen in collagen gels cultured in time with fibroblasts/keratinocytes.
Note increase of new collagen over time (b1-4). (c) Newly deposited collagen fibrils 
(arrows) in a collagen scaffold (arrowhead), two weeks after subcutaneous implantation 
in mice (c1-3) (for clarity, autofluorescence of background collagen was enhanced). For 
Glyaderm® (acellular human dermis), new collagen is indicated by brown staining (c4). 
(d) Newly deposited collagen fibrils (arrow) in various species (d1-4) after implantation 
of a collagen scaffold (arrowhead) in pig (1 month) (d1), Integra® (arrow head) in rat 
(1 week) (d2), Integra® (arrow head) in dog (4 weeks) (d3), and Glyaderm® in human 
(inset shows fibrillar structure) (d4). Scale bars are 50 μm unless indicated otherwise.
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in mice13 and 6) Glyaderm® clinically applied in full-thickness skin defects in humans14. 
We were able to visualize the dermatan sulfate (and hence newly deposited collagen) in 
all species tested, indicating the robustness and species independency of the procedure 
(Fig. 2c,d). In line with the ingrowth of cells from the surrounding tissue into the scaffold, 
newly deposited collagen fibers were most prominent at the border of the scaffold, 
whereas deeper in the scaffold they were thinner and less abundant (Fig. 2c1). Small 
collagen deposits could easily be identified (Fig. 2c2). The newly formed collagen was 
generally oriented in the same direction as the fibers from the original scaffold (e.g. in a 
parallel orientation, see Fig. 2c3). In the pig model (Fig. 2d1), newly formed collagen was 
clearly present alongside the collagen fibers of the original implanted tubular collagen 
scaffold. Newly formed collagen fibers could also be easily identified in rats and dogs 
after implantation (7 and 28 days respectively) with Integra® (Fig. 2d2,d3). Integra® itself 
was not stained by the anti-dermatan sulfate antibody (supplementary Figure S1), even 
though the closely related glycosaminoglycan chondroitin sulfate is abundantly present 
in this commercially available skin substitute. The method was also applicable using the 
human skin derived Glyaderm®. Full-thickness wounds in mice treated with Glyaderm®13 
showed deposition of new collagen 8 days after implantation (Fig. 2c4). Please note 
that due to the strong autofluorescence of elastic fibers in Glyaderm® we used bright 
field instead of fluorescence microscopy. Finally, the method was probed in a clinical 
setting in which burn patients were treated using Glyaderm®14. Biopsies taken 7 days 
after implantation clearly show new collagen in the dense collagenous environment of 
Glyaderm® at the border of the wound bed (Fig. 2d4). Collagen fibers of the surrounding 
native tissue (i.e. in tissue not formed within the biomaterial) were also positive for 
dermatan sulfate in all species tested, as expected.
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Discussion
The results presented above indicate that the anti-dermatan sulfate antibody GD3A12 
is suitable to species independently detect newly formed collagen. Previously, analysis 
has been hampered by the inability to (immuno)histologically distinguish newly formed 
collagen from biomaterial/scaffold collagen. The technique described here offers a 
solution to this problem. However, it is not without potential pitfalls. Although the vast 
majority of dermatan sulfate is associated with collagen as part of the proteoglycans 
decorin and biglycan5, a small fraction may be present associated with other structures 
such as elastin and fibrillin-containing microfibrils15. In addition, dermatan sulfate may 
be part of the proteoglycan versican16 associated with elastic fibers17. However, in 
this study we did not observe any association of dermatan sulfate with elastic fibers 
detected either by autofluorescence or by anti-elastin antibodies (see double staining 
with dermatan sulfate, supplementary Figure S2), indicating that such an association 
was not present in the tissues studied here.
Next to the obvious use in regenerative medicine, the proposed method may be applied 
to other fields of research including cancer biology. Tumor cells spread and invade into 
the surrounding tissues while remodeling the extracellular matrix. It has been suggested 
that in doing so tumor cells make use of newly deposited collagen fibrils18. A widely 
used 3D model to study the migrational behavior of tumor cells is the use of collagen 
gels. The technique described here may be of value in further defining the role of newly 
formed collagen fibrils in tumor biology using such models2.
In conclusion, the detection of newly synthesized collagen based on its association 
with dermatan sulfate and applying the single chain antibody GD3A12 represents an 
inexpensive, fast and easy technique to evaluate the presence and orientation of de 
novo synthesized collagen fibrils in collagen based biomaterials. As such it can be 
applied in many research areas including tissue engineering and tumor biology.
Supplementary Figure S1. Absence of dermatan sulfate in collagenous biomaterials 
before implantation/cell seeding. Immunostaining for dermatan sulfate (green) on 
(a) acellular bovine type I collagen hydrogel, (b) Integra® before implantation and (c) 
Glyaderm® before implantation. Note lack of staining. Scale bars are 50 μm.
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Materials and methods
Materials
Papain, barium acetate, paraformaldehyde, 3,3′-diaminobenzidine tetrahydrochloride 
(DAB), 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI) and protein A were from 
Sigma, St. Louis MO, USA. Chondroitinase B was from IBEX, Montreal, Quebec, 
Canada. Agarose and gel bond film were from Lonza, Rockland, USA, and Tissue Tek 
from Sakura Finetek Europe BV, Alphen aan den Rijn, The Netherlands. Tris-HCl was 
from Invitrogen, Carlsbad, CA, USA. Sodium chloride and magnesium acetate were 
from Merck, Darmstadt, Germany. Lowicryl HM20 was from Aurion, Wageningen, The 
Netherlands and Mowiol 4-88 mounting medium was from Calbiochem, San Diego, CA, 
USA. Bovine serum albumin (BSA) was from PAA laboratories, Pasching, Austria. The 
following antibodies were used: rabbit anti-bovine type I collagen IgG from Millipore, 
Cambridge, UK; mouse anti-bovine elastin IgG from Sigma; rabbit anti-VSV IgG from 
Rockland, Gilbertsville, PA, USA; mouse anti-VSV IgG from mouse hybridoma cell line 
P5D4 from the American Type Culture Collection, Rockville, MD, USA; peroxidase 
labeled mouse anti-VSV IgG from Sigma and mouse anti-Penta-His IgG from QIAGEN 
GmbH, Hilden, Germany; goat anti-mouse IgG Alexa Fluor 488 conjugated and goat 
anti-rabbit IgG Alexa Fluor 594 conjugated from Invitrogen, Eugene, OR, USA. The 
single chain variable fragment antibody GD3A12 selective for dermatan sulfate was 
obtained as described7,19. As a source of this antibody, periplasmic fractions isolated 
from bacteria expressing the antibody were used20. The antibody contains a VSV and 
a HIS tag. 
Supplementary Figure S2. Absence of dermatan sulfate on elastic fibers shown by 
double immunostaining of cryosections of sheep skin for elastin (red) and dermatan 
sulfate (green). Elastic fibers (red, arrow) are negative for dermatan sulfate (green, 
arrow head), and dermatan sulfate is negative for elastin staining. Scale bars are 50 μm.
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Histology 
Paraffin-embedded and frozen tissues were sectioned at 5 μm thickness. Paraffin 
sections were deparaffinized in xylene for 3 × 5 min, followed by a descending series of 
ethanol and processed for immunohistochemistry. Cryosections were air-dried before 
staining. 
Immunofluorescence stainings 
To stain for dermatan sulfate, deparaffinized sections were blocked for 15 min with 1% 
BSA in Tris buffered saline (TBS, 50 mM Tris-HCl pH 7.0 containing 150 mM NaCl). All 
further incubations were performed at ambient temperatures for 45 min and sections 
were washed 3 × 5 min with TBS in between incubations. Antibodies were diluted in 
1% BSA in TBS. Paraffin sections were incubated with antibody GD3A12 (1:5 - 1:20), 
followed by incubation with mouse anti-VSV antibody P5D4 (1:10) and an Alexa Fluor 
488-conjugated goat anti mouse antibody. For double staining with type I collagen, 
antigen retrieval using citrate buffer was applied. Paraffin sections were pretreated with 
citrate (10 mM sodium citrate, pH 6.0) for 20 min at either 95 °C (tissues) or ambient 
temperature (cultured gels). In one occasion boiling temperature was used, but this 
caused damage to the sections. Sections were extensively washed with TBS to remove 
the citric acid buffer and blocked with TBS/BSA. Anti-type I collagen antibody (1:500–
1:1500) was applied and visualized using an Alexa Fluor 594-conjugated goat anti-
rabbit antibody. For detection of dermatan sulfate in implanted collagen scaffolds in 
mice, a rabbit anti-VSV antibody (1:500) was used and visualized using goat anti-rabbit 
IgG Alexa Fluor 488. In the case of double staining of dermatan sulfate and type I 
collagen in mice, dermatan sulfate was visualized using Alexa Fluor 488 conjugated 
mouse anti-Penta-His antibody. 
For double staining of sheep skin cryosections for elastin and dermatan sulfate, the 
sections were air-dried for 30 min. Hereafter, the procedure as described above was 
applied. Mouse anti-bovine elastin antibody was diluted 1:200 and visualized using goat 
anti-mouse IgG Alexa Fluor 594. Dermatan sulfate was visualized using rabbit anti-VSV 
IgG and goat anti-rabbit IgG Alexa Fluor 488. 
For visualization of the nuclei, sections were incubated for 15 min with DAPI (10 μ g/ml 
in PBS). After extensive washings with PBS, the sections were enclosed with Mowiol 
mounting medium. 
For detection of dermatan sulfate in the human skin substitute Glyaderm®, containing 
autofluorescent elastic fibers, peroxidase conjugated mouse anti-VSV IgG (1:100) and 
DAB were used.
Omission of the antibody GD3A12 was taken as a control, and was negative in all cases.
Digestion of dermatan sulfate to evaluate specificity of GD3A12 
To evaluate the specificity of the antibody GD3A12 for dermatan sulfate, cryosections 
were digested overnight at 37 °C with 20 mU/ml chondroitinase B in 25 mM Tris-HCl 
pH 8.0 containing 2 mM magnesium acetate. The next day, the digestion was repeated 
with 20 mU/ml chondroitinase B for another 2 h. As a control, sections were incubated 
in buffer without enzyme.
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Microscopic imaging, equipment and settings 
Images of the in vitro cultured collagen gels were taken with a Leica DM6000 B 
microscope equipped with a Leica DFC 480 camera (20x objective), using Leica 
Application suite V4.3.0. The exposure time was kept constant for all measurements. 
DAPI, Alexa Fluor 488 and 594 were excited with a mercury HBO100 lamp using the 
excitation filters BP410/15 nm BP490/20 nm and BP562/40 nm respectively, and the 
emission was collected after filtering with 430, 500, 593 dichroic mirrors respectively.
All other images were captured with the Olympus FV1000 Confocal Laser Scanning 
Microscope. Photos wereimaged using a 20× objective and a 60× objective. DAPI, 
Alexa Fluor 488 and Alexa Fluor 594 were excited at 405 nm, 488 nm and 559 nm, 
respectively. Using a combination of the beam splitters SMD490 and SDM560, the 
emission was collected with the emission filters BA430-470, BA505-540 and BA575-
675 for DAPI, Alexa Fluor 488 and Alexa Fluor 594, respectively.
For Figs 1c and 2a,b and supplementary Figure S1a, the microscope settings were 
as follows: space resolution 2560 × 1920, pixel dimension 0.012 pixels/μm, image 
depth 32 (RGB), excitation filters: 410/15 (DAPI), 490/20 (AF488), 562/20 (AF594) and 
gamma correction was set at 1. For Figs 1d and 2c,d, the settings were as follows: 
space resolution 1024 × 1024, pixel dimension 1.61 pixels/μ m, image depth 32 (RGB), 
excitation filters 405 (DAPI), 488 (AF488), 559 (AF594), emission filters BA430-470 
(DAPI), BA505-540 (AF488), BA575-675 (AF594). Dichroic beam splitters 490 9DAPI) 
and 560 (AF488) were used. No gamma correction was applied.
Image processing was performed using ImageJ 1.48v (National Institutes of Health, 
USA). Before merging, both brightness and contrast were adjusted similarly for all 
photos including the controls. 
Immuno-electron microscopy
To evaluate the reactivity of the antibody for dermatan sulfate on collagen fibrils, immuno-
electron microscopy was performed on lowicryl HM20 embedded rat kidney samples21. 
The tissue was incubated for 3 h in Somogyi solution [0.1 M phosphate buffer (pH 7.3) 
containing 4% formaldehyde, 0.05% glutaraldehyde and 0.2% picric acid] [22]. After 
cutting, 200 μ m sections were frozen in liquid propane at − 190 °C. Using freeze-
substitution (Leica-KF80) the sections were embedded in lowicryl HM20. Ultrathin 
sections were mounted on nickel grids. For immunostaining sections were blocked 
with 0.25% BSA in phosphate buffered saline (BSA/PBS), followed by an overnight 
incubation at 4 °C with antibody GD3A12 (5× diluted periplasmic fraction in BSA/PBS). 
After washing, bound GD3A12 was visualized using 10 nm gold-sphere labeled protein 
A (1:400 in BSA/PBS) prepared according to Slot et al.23. Subsequently, sections were 
washed in PBS, post-fixed for 5 min in 2.5% glutaraldehyde in 0.1 M phosphate buffer 
(pH 7.4), washed with distilled water, and post-stained with uranyl acetate. Sections 
were examined using a JEOL 1010 electron microscope.
Agarose gel electrophoresis
To analyze the presence of glycosaminoglycans including dermatan sulfate in collagen 
scaffolds/gels, agarose gel electrophoresis was performed. To 40 mg dry weight of the 
samples, 2.5 U/ml papain was added to a total volume of 500 μ l in order to digest 
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proteins. 0.5 μl of the samples was loaded on a 1 mm thick 1% agarose gel in 50 mM 
Ba(Ac)2, pH 5.0, casted on a gel bond film. A marker was included containing 5 ng of 
chondroitin sulfate (CS), 5 ng dermatan sulfate (DS) and 5 ng heparan sulfate. The gel 
was run at 30 mA in electrophoresis buffer (50 mM Ba(Ac)2, pH 5.0) until the front of the 
loading dye had moved about 8 cm into the agarose gel. Subsequently, the agarose gel 
was stained with silver as described by Van de Lest et al.24.
Gels and scaffolds 
All experimental protocols described by Sun et al.25, Nillesen et al.11, van Kilsdonk et 
al.13, de Jonge et al.26, and Ophof et al.12 were approved by the Institutional Animal 
Welfare Committee (DEC) of the Radboud university medical center, Nijmegen, The 
Netherlands. The experimental procedures described by Braziulis et al.8 were approved 
by the Ethics Committee of the Canton Zürich (KEK), Switzerland. The study protocol 
as described by Pirayesh et al.14 was approved by the Ghent University Hospital Ethics 
Committee.
All experiments were carried out in accordance with the guidelines of the Institute of 
Laboratory Animal Research27 and the declaration of Helsinki principles.
Cellularized collagen gels 
The dermal (denovoDerm) and dermal-epidermal (denovoSkin) collagen gels were 
prepared using bovine type I telocollagen seeded either with primary fibroblasts 
only (denovoDerm), or with a combination of primary fibroblasts and keratinocytes 
(denovoSkin), isolated from skin biopsies from 3 individuals who had given informed 
consent, as described by Braziulis et al.8. 50,000 fibroblasts were cultured in DMEM 
supplemented with 10% fetal bovine serum (FBS), 10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid buffer (HEPES), 90 μ g/ml streptomycin and 90 U/
ml penicillin (all compounds from Invitrogen, Basel, Switzerland) for 2, 4 or 6 days 
in compressed collagen gels at 37 °C and 5% CO2. For the dermal-epidermal skin 
substitute, 500,000 keratinocytes were seeded on top of the dermal substitute and 
cultured for another 6 days (12 days in total) in serum free keratinocyte medium. 
Samples were fixed in 4% paraformaldehyde and embedded in paraffin.
Acellular collagen scaffolds implanted in mice 
Flat porous collagen scaffolds were prepared as described by Sun et al.25 from a 
0.4% (w/v) type I collagen suspension in 0.25 M acetic acid. After homogenization, 
the suspension was pipetted in a polystyrene mold, frozen and lyophilized resulting in 
porous collagen scaffolds. Hereafter, the collagen scaffolds were pre-incubated in 50 
mM 2-(N-morpholino)ethanesulphonic acid pH 5.0 (MES) and crosslinked using 33 mM 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 6 mM N-hydroxysuccinimide 
(NHS) in 50 mM MES buffer containing 40% ethanol for 4 h. After multiple washing 
steps with subsequently 0.1 M Na2HPO4, 1 M NaCl, 2 M NaCl, and water, the scaffolds 
were frozen at − 20 °C and lyophilized, followed by sterilization by γ -irradiation (25 kGy, 
Synergy Health, the Netherlands). Collagen scaffolds were incubated in sterile 0.9% 
NaCl and subcutaneously implanted in 7-weeks-old Balb/cByj mice. After two weeks, 
mice were sacrificed and tissue was dissected around the site of implantation, fixed in 
4% paraformaldehyde and embedded in paraffin.
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Tubular acellular collagen scaffolds implanted in pigs 
Tubular collagen constructs of 6 cm in length and an inner diameter of 6 mm were prepared 
as described using a 0.5% (w/v) collagen suspension in 0.25 M acetic acid28. After 
lyophilization the tubes were crosslinked followed by extensive washing, as described 
above. Tubular scaffolds were kept in 70% ethanol before γ -sterilization. Sterilized 
tubular collagen scaffolds were implanted in the ureter of 4-months-old pigs, dissected 
after one month, fixed in 4% paraformaldehyde and embedded in paraffin26. Integra® 
implanted in rat and dog. In rats, Integra®, a commercially available collagen-chondroitin 
sulfate scaffold29, was implanted in a full thickness wound11. After 7 days, rats were 
sacrificed, the wound area dissected, fixed in 4% paraformaldehyde and embedded in 
paraffin11. In dogs, Integra® was implanted according to the Von Langenbeck procedure 
for palatal repair12. Samples were taken 28 days post implantation. Tissue was fixed in 
4% formaldehyde, decalcified in 20% formic acid and 5% sodium citrate12 and imbedded 
in paraffin.
Glyaderm® implanted in mouse and human 
Glyaderm®, a glycerol preserved acellular human dermis containing native collagen and 
elastic fibers9 was produced by the Euro Skin Bank, Beverwijk, The Netherlands. Full 
thickness wounds at the back of 8-week-old mice were implanted with Glyaderm®. After 
8 days, mice were sacrificed, fixed in 4% paraformaldehyde and embedded in paraffin13.
Application of Glyaderm® to a human wound bed was performed and described by 
Pirayesh et al.14. Informed consent was given by all patients. Full-thickness defects were 
engrafted with Glyaderm®. After 1 week, biopsies were fixed in 4% paraformaldehyde 
and embedded in paraffin.
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Summary
A growth factor gradient was prepared in type I collagen scaffolds using a novel method. 
First, a gradient of glycosaminoglycans (GAGs), i.e. heparin, was established in porous 
collagen scaffolds by means of chemically crosslinking with a gradient of 0–10% (w/v) 
heparin. As a second step, heparin-binding fibroblast growth factor 2 (FGF2) was bound 
to these collagen-GAG scaffolds. The FGF2 gradient corresponded to the applied 
heparin gradient. Cell culture experiments showed that the gradient scaffold was 
capable of enhancing cell growth in a concentration-dependent manner.
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Introduction
Gradients of effector molecules, e.g. growth factors and morphogens, are essential for 
embryonic development and stem cell control [1–3]. Therefore, mimicking gradients 
is of interest in the field of regenerative medicine, as they may enhance growth factor 
delivery and subsequent tissue regeneration [4]. The creation of a gradient of signalling 
molecules on collagen-based biomaterials, however, is technically challenging [2,5,6].
During embryonic development, intercellular communication is mediated by extracellular 
diffusion or cell-to-cell transfer of effector molecules potentially resulting in a signalling 
gradient. Communication via cell-to-cell transfer or transcytosis is based on the 
movement of effector molecules across cells or along cellular extensions. Extracellular 
diffusions can be described by three models, e.g. a free diffusion model, a hindered 
diffusion model and a facilitated diffusion model [7,8]. The simplest model for gradient 
formation is a cellular source releasing an effector molecule, which is transported via 
an extracellular diffusion model. Cells close to the source will be exposed to a higher 
concentration of the effector molecule in comparison to cells further away from the 
source leading to distinctive cellular responses [9]. This model is called the threshold 
model [10–12]. Gradients can become more difficult to interpret in the presence 
of multiple effector molecules or cellular sources. In both cases, the outcome of the 
gradient is dependent on the diffusion properties of the released molecules as well 
as the interaction with cellular receptors extracellularly [13,14] and targeted gene 
expression intercellularly [9].
An example of a gradients created by extracellular diffusion can be seen during glandular 
organogenesis where they play a role during epithelial branching patterning and limb 
formation. In the first case, gradients are created by a difference in binding affinity of 
Figure 1 - Schematic overview of a collagen scaffold with a gradient of heparin and 
growth factor.
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fibroblast growth factor 7 (FGF7) and FGF8 to heparan sulfate [14], while in the second 
two sources of effector molecules are present, i.e. the apical ectodermal ridge and the 
zone of polarizing activity forming a complex interplay of effector molecules like bone 
morphogenetic protein (BMP), sonic hedgehog (SHH) and members of the FGF family 
[15].
Research towards the formation and interpretation of gradients has mainly focused 
on embryonic development. During adult homeostasis, however, gradients are still of 
eminent importance. Tissue repair in the lungs is aided by a gradient of chemokines 
guiding circulating leukocytes to an afflicted site as this site releases chemokines 
restricted in diffusion by cell-bound heparan sulfate leading to a gradient [16]. In cutaneous 
wound repair, examples include gradients of chemokines which affect neutrophils and 
macrophages [17] and the VEGF-A gradient important for neovascularization that is 
induced by hypoxia [18,19].
Incorporation of a gradient of effector molecules in tissue-engineered constructs for 
wound repair may further improve their function. To create a tissue-engineered construct 
containing a gradient of effector molecules, we chose type I collagen as a scaffolding 
material and heparin to bind the effector molecules. Heparin is a glycosaminoglycan 
similar to heparan sulfate [20]. It has been shown that heparan sulfate is involved in the 
hindered diffusion model of effector molecules [7,11,14]. 
In this study, we made an effort to establish a growth factor gradient through a 
glycosaminoglycan gradient in type I collagen scaffolds to influence cellular behavior for 
tissue engineering purposes (Figure 1).
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Experimental methods
All solutions were made using MilliQ water.
Preparation of scaffolds
Type I collagen was isolated from bovine achilles tendon [21]. Porous scaffolds [22,23] 
were prepared from homogeneous 0.8% (w/v) collagen dispersions in 0.25 M acetic 
acid in 75 cm2 culture flasks by freezing using a mixture of dry ice and ethanol and 
lyophilisation in a Zirbus lyophiliser (Bad Grund, Germany) [22].
Crosslinking scaffolds with a gradient of heparin
Sucrose was used to stabilize a gradient of heparin in solution. The scaffolds of 8 to 10 
cm in length and 1 cm in width were attached to a gauze and placed in a 15 mL tube 
(Greiner Bio-one). Using the mixer part of the Biologic LP system (Bio-Rad), a gradient 
was created by gradually mixing a solution containing 33 mM 1-ethyl-3(-3-dimethyl 
aminopropyl) carbodiimide (EDC, Fluka) and 6 mM N-hydroxysuccinimide (NHS, Fluka), 
25% sucrose (Sigma) and 10% heparin (Diosynth) (solution A) and a second solution 
containing 33 mM EDC and 6 mM NHS (solution B). This created a gradient from 100% 
solution A at the bottom to 100% solution B at the top of the tube. The scaffold was 
incubated for 16 h in the gradient, washed twice in 0.1 M Na2HPO4 (pH 9.1) for 1 h, 
washed with 1 M NaCl and 2 M NaCl for 2 h and 1 day and subsequently washed with 
distilled water [21]. The gradient scaffold was frozen at -80oC and lyophilized.
To visualize the stability of the gradient, 
fountainpen ink was added to the sucrose 
gradient (Figure 2).
Growth factor binding
Collagen scaffolds were disinfected using 
70% ethanol by four 1 h incubations and 
one overnight incubation. Scaffolds were 
washed with sterile phosphate-buffered 
saline (PBS, pH 7.4) three times shortly, 
four times for 1 h and once overnight. 
Scaffolds were subsequently incubated 
in a solution containing 7 μg FGF2 per 
ml sterile PBS for 1 h at 20oC. Unbound 
FGF2 was removed by washing three 
times with PBS for 5 min.
Figure 2 – A 50 ml tube containing a 
gradient of sucrose and ink to show the 
sucrose gradient. 
0% sucrose
25% sucrose
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Analysis of the scaffold
Primary amine content (TNBS assay) - Primary amine content was evaluated 
spectrophotometrically after reaction with 2,4,6-trinitrobenzene sulphonic acid (Sigma) 
using a glycine calibration curve [24]. Non-crosslinked scaffolds were used as a control. 
A Synergy2 BioTek microplate reader was used for meassurements.
Heparin content - The content of incorporated heparin was determined by hexosamine 
analysis using p-dimethylamino-benzaldehyde [25] with a heparin calibration curve [21]. 
Non-crosslinked scaffolds were used as a control. A Synergy2 BioTek microplate reader 
was used for meassurements.
Analysis of the growth factor gradient
FGF2 staining - Growth factor binding on scaffolds containing a gradient of heparin was 
analysed using immunostaining. A collagen scaffold containing a gradient of heparin 
incubated with growth factor solution was incubated overnight with blocking buffer (PBS 
containing 0.1% (v/v) Tween (PBST) and 3% (w/v) BSA). Scaffolds were incubated 
with rabbit anti–bovine FGF2 antibody (Sigma) in blocking buffer (1:1000) for 90 min. 
Scaffolds were washed in PBS and incubated with alkaline phosphatase conjugated 
goat anti-rabbit IgG (Sigma) in blocking buffer (1:1000) for 90 min. After washing in 
PBS, scaffolds were washed in diethanolamine solution (0.1 M diethanolamine, 0.05 
M MgCl2, pH 9.6). Staining of the scaffolds was performed with NBT/BCIP (nitroblue 
tetrazolium 5-bromo-4-chloro-3-indolyl phosphate reagent) diluted in diethanolamine 
(45 μl NBT, 35 μl BCIP in 10 ml diethanolamine solution) and the reaction was stopped 
by replacing the staining solution with MilliQ.
Cell culture
Normal rat kidney cells (NRK; ATCC CRL-6509) were seeded on collagen scaffolds 8 
to 10 cm in length and 1 cm in width with a gradient of heparin with FGF2 (0.5.106 NRK 
cells per ml DMEM containing 20% (v/v) fetal calf serum and 4 mM glutamine) and were 
analysed at day 2, 4 and 7 of culturing. Scaffolds were washed twice with PBS, fixed 
in 4% formaldehyde in phosphate buffer (pH 7.2), and embedded in paraffin. Sections 
were stained using haematoxylin-eosin [26].
Figure 3 – Heparin content of the created 
gradient (A) showed an increase of bound 
heparin correlating to the amount of heparin 
present in the sucrose gradient. The created 
gradient was analyzed using immunostaining 
for FGF2, which indicated an ascending 
gradient of FGF2 along the scaffold (B).
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Results
Primary amine content
Crosslinking of the scaffold was analysed using a TNBS assay. Compared to non-
crosslinked scaffolds the number of primary amine groups were reduced with 38%±7 
(mean±SD), indicating 38% crosslinking.
Heparin content
A hexosamine assay was used to determine the amount of heparin bound to the 
scaffold after crosslinking. Measuring the heparin content of ten samples taken along 
the scaffold showed that heparin was bound to the scaffolds ranging from 0 to 5.5% 
(Figure 3A), indicating the presence of a gradient.
FGF2 staining
To analyse the binding of growth factor to the heparin gradient on the collagen scaffold, 
immunostaining using an antibody against FGF2 was performed. A gradient was visible 
corresponding to the heparin gradient (Figure 3B). With a higher concentration of 
heparin, more FGF2 staining was observed.
Cell culture
Normal rat kidney (NRK) cells were used to test the bioactivity of the gradient scaffold 
loaded with FGF2. After 2, 4 and 7 days of culturing, haematoxylin-eosin was used to 
localize the NRK cells in the gradient scaffolds. Increased cell numbers were found at 
the side containing 5.5% in comparison to the side containing no heparin. The increase 
in proliferation after 7 days of culturing is shown in Figure 4. These results suggest that 
the gradient of FGF2 resulted in differences in proliferation along the scaffold. 
Figure 4 - Micrographs taken at different locations in 
a collagen scaffold with a heparin–FGF2 gradient, 
after 7 days of culturing. Note that with increasing 
FGF2 concentrations a clear increase in the number 
of cells was found. Sections were haematoxylin-
eosin stained. Pictures were taken at an original 
magnification of 100X.
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Figure 5 – Two alternative approaches towards a gradient of effector molecules. (A) 
Using a diffusion device a gradient of effector molecules is created in a hydrogel [34]. 
The gradient is subsequently transferred to the heparin-collagen scaffold by blotting. 
(B) Using a microfluidic device a gradient of effector molecules is created by dilution in 
mixers. Channels with the various concentrations are led to a dispenser with multiple-
outlets. The dispenser is placed in a device similar to a dot-blot microfiltration system. 
The gradient is transferred to the collagen-heparin scaffold using a vacuum.
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Discussion
The main aim of this research was to create a gradient of effector molecules on a 
collagen scaffold. Here, a gradient was created by crosslinking a collagen scaffold in the 
presence of a gradient of heparin sustained by sucrose. Binding of FGF2 to the scaffold 
with a heparin gradient resulted in a gradient of the applied growth factor, which in turn 
resulted in a concentration-dependent proliferation of normal rat kidney cells in vitro. 
The created gradient scaffold may be a major step forward in regenerative medicine for 
various tissues in both in vitro and in vivo treatments.
Heparin, closely related to the heparan sulfate glycosaminoglycan, is widely used in 
tissue engineered constructs to bind effector molecules [27,28]. One of the effector 
molecules that binds to heparin is FGF2 [29]. We therefore expected FGF2 to bind to 
the heparin crosslinked to the collagen scaffold, which was shown by immunostainings. 
The specific interaction with heparin is a confirmation of earlier studies [27].
FGF2 is part of the fibroblast growth factor family, which is involved in various cellular 
processes [30]. FGF2 is known to influence cellular communication in a concentration 
dependent manner, as e.g. shown by the increased proliferation of human osteosarcoma 
MG-63 cells in fibrin matrices with immobilized FGF2 [31] and the concentration 
dependent generation of neurons and glia form multipotent cortical stem cells [32]. A 
concentration-dependent effect of FGF2 was also found on the normal rat kidney cells 
used here. It has been speculated that one of the principles behind the concentration-
dependent reactions of cells to fibroblast growth factors is that fibroblast growth factor 
receptors on the cell react to different concentrations of fibroblast growth factors [33]. 
The scaffold of approximately 8-10 cm in length is relatively large when compared to 
biological gradients found in embryonic development and adult homeostasis [7,10]. 
Although the large gradient was effective on cells, down-scaling of the gradient is 
needed. New techniques may be based on a direct gradient of effector molecules, made 
onto heparin-containing scaffolds without a GAG gradient (Figure 5).
The first technique we like to postulate is based on a gradient device [34] (Figure 5A), 
which is able to create gradients of 1 cm based on diffusion from an application point. 
More complex gradients can be made with this technique, since two different effector 
molecules can be applied in the application slots (Figure 5A). Initial pilot experiments 
showed that it is feasible to create an FGF2 gradient in a hydrogel (results not shown). 
Further research is needed to determine whether it is possible to transfer the FGF2 
gradient from the hydrogel to collagen-heparin scaffolds or films.
A second potential technique is based on microfluidics [35–37]. Microfluidic based 
devices are used in cell culture, e.g. to study cellular migration by defined gradients 
[38,39]. One could create a gradient using microfluidics by designing a device containing 
several mixers, followed by a dispenser to transfer the various concentrations of effector 
molecule to a collagen-heparin scaffold/film by applying a vacuum (Figure 5B). The 
complexity of the gradient can be adapted by the number of mixers used. 
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Conclusion
Type I collagen scaffolds were prepared with a gradient of glycosaminoglycans and 
FGF2, resulting in differences in cell number along the gradient scaffold after cell 
culture. This opens the possibility to create gradients on tissue engineered constructs.  
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Abstract
Glycosaminoglycans are important for cell signaling and therefore for proper embryonic 
development and adult homeostasis. Expression of genes involved in proteoglycan/
glycosaminoglycan (GAG) metabolism, and of genes coding for growth factors known 
to bind GAGs, were analyzed during skin development by microarray analysis and real-
time quantitative PCR. GAG related genes were organized in six categories based on 
their role in GAG homeostasis, viz. 1) production of precursor molecules, 2) production 
of core proteins, 3) synthesis of the linkage region, and 4) polymerization, 5) modification 
and 6) degradation of the GAG chain.
In all categories highly dynamic up and down regulations were observed during skin 
development, including differential expression of GAG modifying isoenzymes, core 
proteins and growth factors. In two mice models, one over-expressing heparanase and 
one lacking C5 epimerase, differential expression of only few genes was observed.
Data show that during skin development a highly dynamic and complex expression of 
GAG-associated genes occurs. This likely reflects quantitative and qualitative changes 
in GAGs/proteoglycans -including structural fine tuning-, which may be correlated to 
growth factor handling.
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Introduction
During various cell signaling processes, glycosaminoglycans (GAGs), such as heparan 
sulfate (HS), chondroitin sulfate (CS) and dermatan sulfate (DS), play a role in binding, 
guiding and modulating signaling molecules, e.g. growth factors and morphogens (1–3). 
In skin this role can be illustrated by the importance of GAGs in adult wound healing 
(3–7) and in the extracellular matrix architecture formed during dermal development (8). 
A further example to illustrate the importance of GAGs comes from mice overexpressing 
heparanase -an enzyme involved in the degradation of HS-, showing accelerated hair 
growth (9), indicating its involvement in hair follicle morphogenesis and homeostasis. 
Other observations show that HS is involved in hair follicle cycling, sebaceous gland 
morphogenesis and homeostasis (10). Finally, HS and heparanase influence wound 
healing in adult mice by enhancing keratinocyte migration and stimulating blood vessel 
maturation (7).
Inhibition of the expression of genes coding for enzymes involved in GAG modification 
reactions clearly indicate the importance of GAGs during organogenesis, especially with 
respect to growth factor handling. For example mice deficient in Ndst1 (N-deacetylase 
sulfotransferase isoenzyme 1) die neonatally due to several defects in which defective 
sonic hedgehog (Shh) signaling is implicated (11); mice deficient in Hs2st (heparan 
sulfate 2-O sulfotransferase) or Glce (glucuronic acid epimerase) display renal agenesis 
(12,13), whereas mice deficient in Hs6st1 (heparan sulfate 6-O sulfotransferase isozyme 
1) show aberrant signaling of VEGF (vascular endothelial growth factor) and impaired 
lung development (14). A skin phenotype of the above mouse models, however, has not 
been reported.
In general, it is thought that specific modifications of the GAG chain are involved in 
the binding and modulation of signaling molecules resulting in cell-type and/or tissue 
specific reactions (3,15,16). GAG mimetics like the RGTAs (regenerating agents) have 
been used to treat skin disorders and improve skin healing (17). To obtain insight in 
GAG metabolism during skin development we studied the expression of GAG related 
genes covering six functional classes ranging from the synthesis of precursor molecules 
to the synthesis and degradation of GAGs. In addition, we probed the expression of a 
number of (GAG binding) signaling molecules.
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Materials and methods
An overview of the experimental setup on the gene expression during murine skin 
development is given in Figure 1.
Animals for the study on skin development
NIH guidelines for the care and use of laboratory animals (NIH publication 85–23 
Rev. 1985) were followed. The study was approved by the Ethics Committee of the 
Radboud university medical center (DEC 2005-111, project: 81027). C57BL6/j mice 
were obtained from Elevage Janvier (Le Genest Saint Isle, France). Mice aged 90 days 
(90 days post birth [P90]) were used for timed matings and dorsal skin was collected 
at 14 days (E14) and 16 days post conception (E16). At E14 hair follicle development 
is initiated and at E16 appendage formation is almost completed in combination with a 
stratified epidermis and organized dermis (18,19). For the RNA samples of E14, dorsal 
skin of seven embryos from one female were pooled and used for RNA isolation. Skin 
was isolated at E14 by snap freezing the whole embryo in liquid nitrogen followed by 
scraping the skin layer in a cryomicrotome with a scalpel to minimize contamination with 
other embryonic tissues (skin is very thin at this time point). Samples were stored at 
-80 °C. RNA samples for E16 were taken from two females, collecting dorsal skin form 
7 embryos each. In addition, skin from 1 day old pups (P1) and adult mice (P90) was 
collected. At P1 skin is more organized and has been exposed to air (18,19). For the two 
dorsal skin samples for P1, three pups from two females were taken per sample. Two 
adult three months old mice were used for the two dorsal skin samples at P90. Samples 
for RNA isolation for E16, P1 and P90 were collected by removing dorsal skin and snap 
freezing it in liquid nitrogen and storage at -80 °C.
Tissue of genetically modified mice
Skin samples of glucuronic acid epimerase (Glce) knockout mice (E18.5 for expression 
analysis; E17.5 and E18.5 for histological analysis) and of heparanase overexpression 
(Hpse) mice (P70) were provided by Prof. Dr. Jin-Ping Li (Department of Medical 
Biochemistry and Microbiology, University of Uppsala, Sweden) and Prof. Dr. Israel 
Vlodavsky (Vascular and Cancer Biology Research Center Rappaport Faculty of 
Medicine and Research Institute Technion-Israel Institute of Technology, Israel), 
respectively (9,20). For RNA isolation two wildtype and two mutant mice were used of 
both mouse models.
RNA isolation, real time quantitative PCR and 
microarray analysis
Frozen samples were grinded in a micro-dismembrator (Sartorius, Bunnik, The 
Netherlands) and RNA was isolated using the TRIZOL-method (Invitrogen, Paisley, UK) 
in combination with RNeasy Mini kit with DNAse step (Qiagen, Hilden, Germany). RNA 
quality was assessed using the Bioanalyzer system (Agilent Technologies, Amstelveen, 
The Netherlands). The RNA integrity numbers (RIN, 27) were 8.8±0.25 (technical 
replicate N=2), 8.0±0.35, 8.5±0.55 and 7.3±0.2 for E14, E16, P1 and P90 (biological 
replicates N=2), respectively. The same procedure was used for the RNA isolation for 
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the Glce knockout mouse and Hpse overexpression mouse. The RIN was 6.5±0.51 for 
Glce-/- samples and 8.0±0.48 for Glce+/+ and 6.3±0.3 and 7.7±0.6 for HPA-TG and 
HPA-WT, respectively (all biological replicate N=2).
Gene Chip Mouse exon 1.0 ST Arrays (Affymetrix, High Mycombe, UK) were used 
to analyse gene expression for E14, E16, P1 and P90 using 1 μg of RNA per chip. 
Expression data were preprocessed to check sensitivity and specificity of the results 
based on Kadota et al. (2009) as shown in Uijtdewilligen et al. (2016) (18,22). Gene 
level expression data were calculated for the CORE transcripts (probe sets supported 
by RefSeq mRNAs) using Affymetrix Expression Console software with quantile 
normalization (all arrays are considered to have an equal intensity distribution), GC 
content background correction (probes with high GC-content hybridize better, corrected 
for with built-in probes with different known GC-contents) and summarization with the 
Figure 1 – Experimental setup used for the analysis of gene expression involved in GAG 
biology during skin development in mice. Based on literature data, specific time points 
in skin development were selected. (A) A mouse embryo at 14 days post conception. 
RNA was isolated, verified and subsequently analysed with GeneChip exon arrays (B) 
and TLDA gene expression cards (C).
80
Chapter 5
RMA algorithm (23). Data were imported into GeneSpring GX 7.3 (Agilent Technologies), 
duplicates were averaged and the expression of each transcript was normalized to the 
median per array.
Real Time-Quantitative PCR (qPCR) was performed using custom designed Taqman 
Low Density arrays (TLDA) (Applied Biosystems, Nieuwerkerk aan de IJssel, The 
Netherlands) containing probes against genes involved in GAG metabolism and GAG 
binding proteins (Supplementary data table 1). Glce and Hpse samples were analyzed 
using qPCR using custom designed TLDA with an adapted design containing additional 
GAG related genes (Supplementary data table 2).
For the TLDA cards, 100 ng cDNA in Taqman Universal PCR Master Mix (Applied 
Biosystems) was loaded on the TLDA card per slot and run on a 7900HT Fast Real-Time 
PCR System (Applied Biosystems). Expression was analyzed based on the threshold 
cycle (Ct) which was obtained using the SDS 2.3 software and RQ Manager 1.2 of 
Applied Biosystems using the combined expression data of the tested TLDA cards. In 
Microsoft Excel the reference genes for ΔCt calculation were checked for stability of 
expression by analyzing the results of the reference genes across all used TLDA cards 
and selecting the reference genes with the smallest deviation across the cards tested. 
Subsequently ΔCT values were calculated using a reference gene with the smallest 
difference between the average Ct found for the gene of interest and for the reference 
gene. The obtained ΔCt values were further processed using the 2-ΔΔCt method using P90 
as a calibration point in case of the developmental study, and the wildtype background 
(C57BL6 mice) data in case of the two mouse models (24).
Statistical methods
Statistical significance of the exon array data was analyzed using ANOVA and Benjamini-
Hoghberg multiple testing correction (25). Statistical significance of the TLDA card data 
was tested with an unpaired T-test (2-tailed) using Microsoft Excel. Data with a statistical 
threshold of p<0.10 and a fold threshold of >2.0 were considered statistically significant. 
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Table 1: Comparison of the number of differentially expressed genes during 
skin development in mice (p<0.10, fold>2.0) based on real-time qPCR and 
on exon array analysis.
* P values for the exon array measurements were calculated using 
Benjamini–Hochberg multi-testing correction. P values for the TLDA assay 
were calculated using an unpaired T-test.
Overlap refers to genes differentially expressed in both TLDA card and exon 
array.
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Results
Genes involved in glycosaminoglycan (GAG) synthesis, modification and degradation 
were studied during skin development at 14 and 16 days post conception (E14 and 
E16, respectively) and at one day post birth (P1), and compared to mature skin of a 3 
month old mouse (P90). In addition, two mouse models, viz. a Glce knockout mouse 
(E18.5) and a HPSE overexpression mouse model (P70) were analysed. Taqman 
low density array (TLDA) cards were designed to contain genes involved in GAG 
metabolism (Supplementary data table 1 and 2). The expression data obtained using 
TLDA cards and exon arrays were screened for genes with 2-fold differential expression 
at a statistical threshold of p<0.10 (Tables 1, 2, 3 and 4, Supplementary data tables 4, 
5 and 6).
In Tables 1-3 and Supplementary data table 3, an overview is given of the differentially 
expressed genes applying TLDA cards and exon arrays. In all categories of genes 
involved in GAG metabolism, i.e. production of precursor molecules, core proteins, 
synthesis of linkage region, and polymerization, modification and degradation of the 
GAG chain, differences in expression were found (Tables 1-3). This indicates a highly 
dynamic expression pattern during skin development. Interestingly, some isoenzymes 
were up, whereas other isoenzymes were down regulated, further stressing metabolic 
complexity. This is for instance the case with GFPT1 and 2, both rate limiting enzymes 
involved in the production of hexosamines, and the isoenzymes HS 3-O sulfotransferase 
6 and 3b1.
With respect to the core proteins, differential expression was found for both HS and 
CS/DS proteoglycans. Differential expression was found for two of the four syndecans, 
viz. Sdc1 and Sdc4, three of the six glypicans, viz. Gpc2, Gpc3 and Gpc6, and for 
Hspg2 (Table 2 and 3). The syndecans were down regulated, while the glypicans were 
upregulated, indicating an embryonic role for glypicans as described in literature (4,26). 
Hspg2, a secreted HS presenting proteoglycan coding for perlecan (3), was found to 
be upregulated (Table 2 and 3). Based on the exon array the CS/DS core protein of 
versican (Vcan) was upregulated at all time points (Supplementary data table 5).
The upregulated expression of genes involved in the synthesis of the linkage region may 
signal increased GAG synthesis during development since after the formation of the 
linkage region the GAG chain is formed. For HS polymerization differential expression 
was found for e.g. Extl1 and Extl2. Extl1 showed down regulation at E14 while Extl2 
was upregulated, both enzymes are involved in the initiation and elongation of the HS 
chain (27).
During and after synthesis of the glycosaminoglycan chain, disaccharide units within the 
chain are specifically modified. These modifications determine which effector molecules 
can bind to the chain, and thus play a role in cell signaling (1,2). Upregulated expression 
was found for three of the four N-deacetylase/N-sulfotransferases (Ndst; TLDA cards, 
Table 2), especially isoenzyme Ndst3. Upregulation was also found for two out of 
seven genes coding for 3-O-sulfotransferases (Hs3st1 and Hs3st3b1),  involved in 3-O 
sulfation of GlcNS and GlnNAc residues, whereas one was down regulated (Hs3st6).
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The GlcNS and GlcNAc residues can also be 6-O sulfated by 6-O-sulfotransferases 
(Hs6st) (27) and selectively desulfated extracellularly by two sulfatases (Sulf1 and Sulf2) 
aided by two cofactors (Sumf1 and Sumf2) (3,27,28). Hs6st2 was upregulated at all 
time points (Table 3). Sulf1 was upregulated during embryonic development, whereas 
Sumf2 was upregulated at E14 (Table 2 and 3). These results indicate that specific 
expression of GAG modifying enzymes may play a role in specific cellular signaling 
during skin development.
Within the class of genes encoding for GAG chain degradation enzymes, two genes 
were differentially expressed. Heparanase expression was down regulated at E14 
and P1 (Table 2 and 3), whereas N-sulfoglucosamine sulfohydrolase (Sgsh) was 
downregulated during embryonic development at E16 (Table 2) and at E14 (Table 3).
In addition to genes involved in GAG metabolism, the TLDA card contained 37 genes 
encoding growth factors, which were also present in the microarray (Table 2 and 3). 
Differential expression was found by both TLDA card and microarray analysis for 10, 
9 and 4 growth factors at E14, E16 and P1 respectively. Examples are insulin-like 
growth factor 2 (Igf2), wingless-related integration site 6 (Wnt6) and Wnt7b. Igf2 was 
dramatically upregulated at all time points, as expected based on previous research 
(18). Wnt6 was also upregulated at all time points, while Wnt7b was upregulated only 
during embryonic development.
Next to their expression during development, gene expression of GAG associated 
genes was studied in a Glce (glucuronyl epimerase) knockout mouse model and a 
heparanase overexpression mouse model using TLDA cards. In the Glce knockout 
mice six genes were differentially expressed (Table 4). Three of them are involved in 
CS and DS proteoglycans, and were downregulated, i.e. aggrecan (Acan), asporin 
(Aspn) and chondroitin sulfate N-acetylgalactosaminyltransferase 2 (Csgalnact2). 
Up/down regulation was not found for HS related genes, except for Glce, which was 
downregulated as expected. For the heparanase overexpression mouse model, in 
which a human heparanase was overexpressed (9), the results showed only one gene 
to be differentially expressed, i.e aggrecan (Acan) which was 2.5 fold upregulated. The 
complete results of both the Glce knockout mouse and Hpse overexpression mouse are 
given in Supplementary data table 6. 
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Table 2: Differentially expressed GAG related genes during skin development in mice in 
comparison to mature skin (p<0.10) based on real-time qPCR.
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Numbers in italic are significant (p<0.10); numbers in bold are >2 fold differentially 
expressed. Gene symbols indicated with a †-symbol are normalized using GAPDH as a 
reference gene. Gene symbols indicated with a ‡-symbol are normalized using TBP as 
a reference gene. Genes, for which a signal was not or only partly detected at a given 
timepoint or multiple timepoints and therefore a fold change and/or p-value could not 
be calculated based on the available data, are given as ‘not detected’. Gene symbol for 
which all timepoints were classified as ‘not detected’ do not show a symbol for the used 
reference gene due to lack of data for a calculation.
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Discussion
GAGs play a regulating role during embryonic development of various organs (1–3). 
Therefore, we examined the expression of genes involved in GAG metabolism during 
skin development using custom designed Taqman Low Density Arrays (TLDA card) 
and exon arrays. To structure the data we studied gene expression in six functional 
classes, viz. the production of precursor molecules, the synthesis of core proteins and 
the linkage region, and the synthesis, modification and degradation of the GAG chain 
proper. In addition we studied a number of growth factors, since GAGs are involved in 
their regulation including growth factor diffusion and signaling (29).
With respect to core proteins, the heparan sulfate proteoglycans syndecan and glypican 
showed notable differential expression (Table 2 and 3). Glypicans play an important 
role in development and cell signaling (26,30–33), and we found upregulation of 3 out 
of 6 glypican core proteins. Gpc3 was upregulated during embryonic development and 
one day post birth, suggesting that this glypican has a role during skin development. A 
possible function of Gpc3 in skin has been suggested for the Gpc3-null mouse, which 
showed pigmentation defects (34). Humans deficient in Gpc3 suffer from the Simpson-
Golabi-Behmel syndrome (SBGS). Based on the symptoms of SGBS and the phenotype 
found for the Gpc3-null mice, it has been suggested that Gpc3 is involved in the 
regulation of hedgehog signaling (31), a signaling pathway involved in skin appendage 
formation (35,36). Surprisingly, the Gpc3-null mice did not show a defect in appendage 
formation (34), indicating a functional but not essential role. Further research is needed 
to elucidate the role of Gpc3 and the two other differentially expressed glypicans, i.e. 
Gpc2 and Gpc6.
Syndecans are described to take part in adult wound healing (4,6,37). We found 
downregulation of the core proteins of two syndecans during embryonic development, 
which could indicate that these proteoglycans do not play a major role during skin 
development. In literature, however, it has been shown that Sdc1 is involved in hair 
follicle development based on immunohistochemical data (38,39).
In the class of GAG chain polymerization, we found differential expression of genes 
encoding for the initiation of HS or CS/DS synthesis. HS chain polymerization is initiated 
by the addition of GlcNAc by Extl2 (40) or Extl3 (41), while CS/DS chain polymerization 
is initiated by the addition of GalNAc by Csgalnact1 (42). Extl2 was upregulated during 
early skin development (Table 2), while Csgalnact1 was downregulated (Supplementary 
data Table 5), which suggests that during early skin development HS production is 
stimulated in comparison to CS/DS production.
Enzyme mediated chemical modifications of the GAG chains result in the creation 
of specific binding sites for effector molecules (43). Enzymes forming the class of 
N-deacetylase/sulfotransferases (Ndst’s) are initiating elements in this respect. 
Especially Ndst3 was upregulated, being one of four enzymes responsible for the 
removal of the acetyl group from the N-acetylated glycosamine and for the addition of a 
sulfate group. The additional expression of Ndst3 in combination with Ndst1 and Ndst2 
points to the fine-tuning of HS chains for specific recognition of ligands. Ndst3 has a 
higher deacetylation activity in comparison to the N-sulfotransferase activity, while Ndst1 
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and Ndst2 have a slightly higher N-sulfotransferase activity (44). In addition, the data 
on the expression of heparan sulfate 3-O sulfotransferases (Hs3sts) (45) and heparan 
sulfate 6-O-sulfotransferases (Hs6sts) (46) suggest dynamic and specific modification 
of HS chains.
Three genes encoding for enzymes involved in HS and CS/DS degradation were 
differentially expressed, one of them being Hpse (heparanase). Hpse is down regulated 
at E14 and at P1, but not at E16 at which time point hair follicle development is taking 
place. Hpse has been reported to be involved in this process (47,48).
Glycosaminoglycans are involved in growth factor regulation during developmental 
processes (1–3). We therefore studied 37 growth factors implied in skin development. 
A number of genes encoding growth factors were differentially expressed during 
development and the data are in line with earlier results for e.g. Igf2 (18), Wnt6 and 
Wnt7b (49). Although speculative, the dynamics in GAG structure may be correlated to 
the dynamics of growth factors.
Next to skin development we also studied gene expression in skin of a Glce (glucuronyl 
epimerase) knockout mouse and a Hpse (heparanase) overexpression mouse (9,12). In 
the Glce knockout mice relatively few genes were differentially expressed, suggesting 
that skin is relatively unaffected by the lack of Glce in line with the observation that 
skin in these mice is phenotypically normal (20). The skin phenotype of the Hpse 
overexpression mouse shows accelerated hair growth (9). Gene expression analysis of 
this model showed only one differentially expressed gene (aggrecan).These results may 
touch upon the regulation of translation of mRNAs coding for GAG related enzymes. 
Enzymes involved in the synthesis and modification of GAGs as well genes coding for 
(some) growth factors share a common alternative translation mechanism via IRES 
sites (50,51). In general mRNAs are translated by the ribosomal scanning mechanism 
which scans for short leader sequences of 50 to 70 nucleotides (51,52). The leader 
sequences of the HS modifying enzymes and growth factors are characterized by 
long but structured sequences, which are not recognized by the ribosomal scanning 
mechanism (51,52). Within these sequences internal ribosomal entry sites (IRES) allow 
alternative translation e.g. under stress conditions (52). This indicates that in addition to 
mRNA levels an additional control mechanism on the translational level may be present.
Taken the data together, it is concluded that a highly dynamic expression of genes 
involved in GAG metabolism and in GAG-binding growth factors is associated with skin 
development. This indicates the importance of fine tuning of GAG structures during 
developmental processes. Further studies should focus on the biochemical analysis of 
the GAGs chains themselves.
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Table 3: Differentially expressed GAG related genes during skin development in mice 
in comparison to mature skin (p<0.10) based on gene Chip Mouse Exon 1.0 ST Arrays
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Numbers in Italic are significant (p<0.10); numbers in bold are >2 fold differentially 
expressed. Genes indicated as ‘not measured’ represent genes for which probes were 
not available on the used exon array version.
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Table 4: Differentially expressed genes in C5 epimerase 
(Glce) knockout mouse (p<0.10) based on real-time qPCR. 
Numbers in Italic are significant (p<0.10); numbers in bold are 
>2 fold differentially expressed.
All genes were normalized using 18S RNA as a reference 
gene.
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99
Dynamic expression of genes involved in proteoglycan/GAG metabolism during skin development 
100
Chapter 5
101
Dynamic expression of genes involved in proteoglycan/GAG metabolism during skin development 
102
Chapter 5
103
Dynamic expression of genes involved in proteoglycan/GAG metabolism during skin development 
104
Chapter 5
105
Dynamic expression of genes involved in proteoglycan/GAG metabolism during skin development 
106
Chapter 5
107
Dynamic expression of genes involved in proteoglycan/GAG metabolism during skin development 

Chapter 6
Overexpression of heparanase 
and loss of heparan sulphate 
are involved in emphysematous 
lesions
Nicole C. Smits1,2, Peter J.E. Uijtdewilligen1, Antoine A. Robbesom1, 
Mieke M. J. F. Koenders1, Elly M. M. Versteeg1, Johan van der Vlag3, 
Jo H. Berden3, Israel Vlodavsky4, Eyal Zcharia4, Jin-ping Li5, 
Johan Bulten6, P. N. Richard Dekhuijzen7 and Toin H. van Kuppevelt1
1 Department of Biochemistry, Radboud university medical centre, Nijmegen Centre for 
Molecular Life Sciences, Nijmegen, The Netherlands 
2 Department of Medicine, Heart and Vascular Research Center, Geisel School of 
Medicine at Dartmouth, Hanover, NH, USA 
3 Nephrology Research Laboratory and Department of Nephrology, Radboud university 
medical centre, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands
4 Cancer and Vascular Biology Research Centre, The Bruce Rappaport Faculty of 
Medicine, Haifa, Israel
5 Department of Medical Biochemistry and Microbiology, Biomedical Centre, Uppsala 
University, Uppsala, Sweden, Departments of 
6 Pathology, Radboud university medical centre, Nijmegen, The Netherlands 
7 Pulmonary Diseases, Radboud university medical centre, Nijmegen, The Netherlands 
110
Chapter 6
Abstract
At the time of clinical diagnosis, the process of parenchymal destruction, characteristic 
for emphysema, is already in an advanced state and this hampers the identification of 
early molecular alterations. In this study we took the somewhat unconventional approach 
to evaluate lung specimens from individuals on basis of early signs of microscopic 
emphysema. The overall aim of the study was to determine which extracellular matrix 
(ECM) components are affected in the initial stage of human emphysema, and if similar 
alterations can induce emphysematous lesions in mice. 
Four groups of specimens were analysed by immunohistochemistry to study alterations 
of ECM components. Three groups were made based on the destructive index (DI), 
the most sensitive morphological parameter for emphysema, and on the mean linear 
intercept (MLI). Groups included 1) normal tissue (DI<30%, MLI normal, n = 6), 2) 
slightly affected tissue (DI 30%-80%, MLI normal, n = 8), and 3) moderately affected 
tissue (DI>80%, MLI increased, n = 7). For comparison, specimens from patients with 
severe airflow limitations/emphysema were included as 4th group. 
In human, an increase in DI correlated with a specific decrease in heparan sulfate 
(HS) proteoglycans (both side chain and core protein), and an increase in heparanase 
expression. Other matrix components such as elastin, collagens and laminin were 
not correlated.  The lungs of genetically modified mice that overexpress heparanase 
(HPSEtg) were evaluated as a possible animal model for emphysema. The prime 
molecular changes found in human lungs were mirrored in the lungs of HPSEtg mice, 
whereas these mice developed age-related emphysematous lesions. 
Loss of heparan sulfate and increase of heparanase in parenchymal lung tissue are 
associated with the development of emphysema in humans and induce emphysematous 
lesions in mice. 
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Introduction
Pulmonary emphysema is defined as “a condition of the lung characterised by abnormal 
permanent enlargement of airspaces distal to the terminal bronchioles, accompanied 
by the destruction of their walls, and without obvious fibrosis” [1–3]. Emphysema is a 
disabling progressive disease that takes many years to develop, cigarette smoking being 
a main risk factor [4, 5]. It is generally thought that proteases and free radicals released 
by inflammatory cells and induced by chronic cigarette smoke exposure overwhelm 
the anti-proteolytic and anti-oxidant defences [4, 6, 7], and mediate destruction of lung 
tissue [8–11] and impede repair [12, 13]. 
A major challenge in research on early pathogenic events of emphysema is the time 
span between initiation and clinical manifestation. At the time of clinical diagnosis 
the process of parenchymal destruction is already in an advanced stage, precluding 
identification of early molecular events. Morphological analysis of lung parenchyma 
allows for early identification of emphysematous lesions. This especially holds for the 
destructive index (DI), which is a measure for early parenchymal destruction and has 
a high sensitivity towards mild forms of emphysema [14]. The DI is a more sensitive 
parameter in comparison to the main linear intercept (MLI), which is a parameter for 
airspace enlargement and is generally used for morphometric analysis of emphysema 
[15].
In addition to proteases and oxidative stress (free radicals) that cause destruction of lung 
tissue, an impeded repair may also play a role in the pathogenesis of emphysema [16, 
17]. Maintenance of structural lung tissue after injury as well as tissue repair requires 
production of numerous extracellular matrix (ECM) components in proper quantities and 
sequence. In lung alveoli, the ECM forms a strong expansile framework that supports 
the alveolar epithelial-capillary interface. ECM molecules, in particular proteoglycans, 
may affect inflammatory processes as observed in tissue repair by interaction with 
and regulation of the activity of inflammatory mediators [18, 19]. In emphysema, lung 
tissue is not able to restore the integrity of alveolar tissue after chronic, smoke-induced 
damage. In this respect, impaired repair may imply an abnormal ECM, resulting in 
altered structure and function of tissue. 
Since loss of elasticity is an important hallmark of emphysema most attention towards 
the underlying pathogenesis has focused on elastin as the main target of destruction. 
However, little is known about destruction of individual ECM components at the 
early onset of emphysema. Research interest is changing from the abundant fibrillar 
components to the more regulatory molecules in the ECM like glycosaminoglycans, 
including heparan sulfate (HS) [20–22], chondroitin sulfate and dermatan sulfate [16, 
23]. 
Proteoglycans are proteins with one or more covalently attached glycosaminoglycans. 
The best studied glycosaminoglycan is HS, known to bind and modulate various 
cytokines and growth factors, such as fibroblast growth factor 2 (FGF2) and vascular 
endothelial growth factor (VEGF) [19], which play a role during inflammatory processes. 
For the binding of signalling molecules the sulphation pattern of the glycosaminoglycan 
is important [23]. It has been shown for instance that during idiopathic pulmonary fibrosis 
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the 6-O sulphation of HS is altered, which may lead to aberrant regulation of the fibrotic 
responses to transforming growth factor beta 1 [24]. 
Various knock out mouse models for genes involved in HS-proteoglycan biosynthesis 
have shown that altered expression can lead to altered inflammatory reactions [23]. 
For instance, syndecan 1, a membrane bound HS proteoglycan, is involved in the 
regulation of neutrophils in injured lungs [25]. HS plays a role in the phenotype of 
type I and type II alveolar cell in the lung [26]. The basal membrane beneath type I 
alveolar cells is more sulfated in comparison to the basal membrane beneath type II 
cells and it has been shown that sulphation of glycosaminoglycans  plays a role in the 
transdifferentiation of type II to type I alveolar cells [26]. In general, it is assumed that 
HS has an anti-inflammatory effect [18] and is involved in the regulation of stem cells 
[26]. The involvement of chondroitin- and dermatan sulfate in pulmonary emphysema 
has been shown in a RNA interference study for chondroitin sulfotransferase 3 (Chst3), 
an enzyme involved in 6-O sulphation. Inhibiting expression of Chst3 resulted in a 
decrease in the macrophage accumulation during the inflammatory response [27].
In this study, we focussed on ECM components, especially heparan sulfate 
proteoglycans, in lung tissue from subjects with early signs of tissue destruction as 
revealed by morphometric analysis. Molecular alterations found were mimicked in lung 
tissue from genetically modified mice overexpressing human heparanase, an enzyme 
that degrades heparan sulfate [28], and the lungs were analysed for emphysematous 
lesions.  
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Materials & Methods
Materials
Chemicals and antibodies
All chemicals were purchased from Merck (Darmstadt, Germany), unless stated 
otherwise. Alexa 594-conjugated goat anti-rabbit IgG, Alexa 488-conjugated goat 
anti-mouse IgM (µ chain), and Alexa 594-conjugated goat anti-mouse IgG2b were 
from Molecular Probes (Eugene, OR). FITC-conjugated donkey anti-goat IgG, mouse 
anti bovine α-elastin (clone BA-4), and rabbit anti-EHS mouse laminin were from 
Sigma Immuno Chemicals (St. Louis, MO). Rabbit anti bovine-type I collagen was 
from Chemicon International, Inc. (Temecula, CA). Goat anti human-type IV collagen 
was from Southern Biotechnology Associates (Birmingham, AL). Mouse anti-human 
heparanase 1 (clone HP3/17) was from Insight Biopharmaceuticals Ltd. (Rehovat, 
Israel). Mouse anti-human CD4 and CD8 were from Dakopatts (Glostrup, Denmark). 
Peroxidase labelled goat anti-mouse IgG was from Thermo Scientific (Rockford, USA). 
Mowiol (4-88) was obtained from Calbiochem (La Jolla, CA). Aminoethyl carbazole (red) 
substrate kit was from Zymed Laboratories Inc. (San Fransisco, CA). Mouse monoconal 
antibody 6B6, directed against human decorin, a dermatan sulfate proteoglycan, was 
from Seikagaku (Tokyo, Japan). Goat polyclonal antibody Bl31 [29] was directed against 
the core protein of human agrin (a HS proteoglycan). Mouse monoclonal antibody JM72 
[30] was directed against domain AGR10 of the core protein of human agrin. Mouse 
monoclonal anti-rat HS antibody JM403 was directed against a HS domain containing 
glucuronic acid-rich sequences with N-unsubstituted glucosamine units [31, 32]. All 
incubations were performed at ambient temperature (22 °C) unless stated otherwise. 
Human lung specimens 
Lung tissue was obtained from 21 patients with various degrees of microscopic 
emphysema  and from 3 patients with evident airflow limitation. Informed consent 
was obtained from each patient, and the study was approved by the local ethics 
committee. Characteristics of the study group are given in Table 1. Specimens from 
patients with microscopic emphysema were subdivided into groups based on the DI, 
the most sensitive morphological parameter for emphysema, and the MLI (see below 
for morphometry). Patients were grouped as follows: 1) normal tissue (DI<30%, MLI 
normal), 2) slightly affected tissue (DI 30%-80%, MLI normal), and 3) moderately 
affected tissue (DI>80%, MLI increased). Lung tissue was obtained during lobectomy for 
lung cancer at the University Lung Centre Nijmegen or the Rijnstate Hospital Arnhem, 
the Netherlands. Samples derived from the upper and the lower lobes, and from the 
left and right lung were examined. Specimens (1 cm3) were taken from resected lung 
lobes, not showing any sign of the underlying disease for which the patient underwent 
surgery. For comparison, lung tissue from patients with severe emphysema, (patients 
who underwent lung volume reduction surgery, n = 3) were included. 
Lung function tests were performed before surgery. Static and dynamic lung function 
tests were performed with a wet spirometer and with a closed circuit helium dilution 
method (Pulmonet III, Sensormedics, Bilthoven, The Netherlands). Diffusion capacity 
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for carbon monoxide per liter/lung (alveolar) volume (DL,CO/VA) was measured with 
the single breath-holding carbon monoxide method (Sensormedics 2450), and was 
corrected for actual hemoglobin. Measurements were performed at least 12 h after 
smoking. Predicted spirometric values were derived from the ERS standards. 
Morphological characterisation of lung specimens
Parenchymal destruction
The degree of emphysema was evaluated by the DI, using a microscopic point count 
technique [14, 15]. Microscopic fields were selected, devoid of large bronchi(oli), 
vessels, collapsed tissue, or extensive fibrosis. From each lung specimen, an average of 
5 different sections was used, and representative non-overlapping fields were selected. 
Alveolar, and duct spaces lying underneath the counting points were evaluated for 
the presence of destruction. Destruction was defined on one or more of the following 
criteria: [1] at least two alveolar wall defects, [2] at least two intraluminal parenchymal 
rags in alveolar ducts, [3] clearly abnormal morphology, or [4] classic emphysematous 
changes [14]. The percentage of all the points falling into the several categories of 
destroyed airspaces was computed to reveal the DI. In general, 750 counting points 
were analysed per specimen. 
Airspace enlargement
Enlargement of the airspaces was determined by the MLI measurement technique 
originally described by Dunill [33], which reflects the average size of alveoli. To 
determine the MLI, the same images as described above were used. A transparent 
sheet with 10 horizontal and 11 vertical lines was laid over the images, and intercepts of 
alveolar walls with these lines were counted. Values were corrected for tissue shrinkage 
by measuring the dimensions before and after histological processing. The correction 
factor was 0.832, in accordance with data from Weibel [34].
Immunohistochemistry
Cryosections (4-5 µm) were rehydrated for 10 min in PBS, blocked in PBS containing 
2% (wt/vol) bovine serum albumin (BSA) for 20 min, and incubated with the primary 
antibody for 60 min. Following each incubation, cryosections were washed in PBS (3 x 
5 min). Antibody JM72 was used at 1:250 dilution, anti-heparanase 1 antibody was used 
at 1:200 dilution, anti-type I collagen, antibody Bl31, antibody JM403, and all secondary 
antibodies were used at 1:100 dilution. All other primary antibodies were used at 1:50 
dilution. Cryosections were fixed in 96% ethanol, air dried, and embedded in Mowiol 
(10% (wt/vol) in 0.1 M Tris-HCl, pH 8.5/25% (vol/vol) glycerol/2.5% (wt/vol) NaN3). 
Next to fluorescent detection, heparanase expression was also detected using an 
aminoethyl carbazole (red) substrate kit. Briefly, sections were rehydrated for 10 min 
in Tris-buffered saline (TBS), blocked in TBS containing 1% (wt/vol) BSA for 30 min, 
and incubated with the anti-heparanase 1 antibody for 60 min. Sections were washed 
in TBS, and incubated with 1000-fold diluted peroxidase labelled goat anti-mouse for 
60 min. Sections were washed in PBS for 5 min, rinsed in 50 mM NaAc buffer (pH 
5.0), and peroxidase activity was detected using aminoethyl carbazole (red) substrate. 
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Figure 1. Scatter plots showing the relation between staining for extracellular matrix (ECM) 
components and the destructive index (DI).  Sections of human lung specimens with 
normal (DI<30%, MLI normal), slightly affected (DI 30-80%, MLI normal), or moderately 
affected (DI>80%, MLI increased) parenchyma were incubated with antibodies against 
heparan sulfate (HS; A), heparanase (B), elastin (C), decorin (D), type IV collagen (E), 
and laminin (F). Immunoreactivity was scored using semi-quantitative criteria (-, no 
reactivity; +/-, weak reactivity; +, strong reactivity; +/+, very strong reactivity). Note that 
staining intensity for HS decreased with increasing DI, whereas staining for heparanase 
increased with increasing DI. There were no differences in staining for other ECM 
components such as elastin, decorin, type IV collagen, and laminin between the three 
groups. 
NS, not significant; DI, destructive index; MLI, mean linear intercept; ECM, extracellular 
matrix
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Sections were rinsed in water, counterstained with hematoxylin, washed with running 
tap water for 10 min, further washed with demineralised water for 5 min, and embedded 
in Kaiser’s gelatin. As controls, primary or conjugated antibodies were omitted. Lung 
sections were randomly coded, and immunoreactivity was scored independently using 
semi-quantitative criteria (-, no reactivity; +/-, weak reactivity; +, strong reactivity; ++ 
very strong reactivity) by two observers. Scoring between the observers was consistent 
as deduced from regression analysis (r2 = 0.82–0.92).
Immunohistochemical detection of inflammatory cells was performed on 4 μm 
paraformaldehyde-fixed, paraffin embedded lung tissue sections. The numerical density 
of inflammatory cells in lung parenchyma was determined, including alveolar wall tissue. 
Cells within the lumen of conducting airways and blood vessels were not included. The 
density of inflammatory cells (CD4 and CD8 positive cells) in lung parenchyma was 
determined by and expressed as a percentage of total cell numbers. Total cell numbers 
were defined as the total number of nuclei. Ten randomly selected, non-overlapping 
fields at a magnification of 400× were counted in each tissue section. Using this method, 
up to 5,000 cells were counted in each section. 
Table 1. Characteristics of patients including morphometric analysis (DI and MLI)
Ex, ex-smokers, not smoking for at least one year; C, current smokers; DI, Destructive 
Index; MLI, Mean Linear Intercept; FEV1, forced expiratory volume in 1 second; % pred, 
percentage of predicted value; VC, vital capacity; TLC, total lung capacity; RV, residual 
volume; KCO, diffusion capacity for CO; LVR, lung volume reduction.
*All values are presented as means ± SD. **: DI and MLI were not assessed due to the 
advanced parenchymal destruction of the tissue
( ): indicates number of patients if different from numbers indicated as n-number
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Figure 2. Expression of extracellular matrix components in lung tissue.  Lung tissue 
from morphologically characterised human specimens with Destructive Index (DI) 
<30%; MLI normal (A), DI 30-80%; MLI normal (B), DI>80%; MLI increased (C), and 
from lung volume reduction (LVR) patients (D) was incubated with antibodies against 
the alveolar basement membrane components heparan sulfate (HS; antibody JM403 
(A1-D1), agrin (antibody JM72 (A2-D2, and antibody Bl31 (D3-D3), type IV collagen 
(A4-D4), and laminin (A5-D5). Note the decrease in HS, and agrin staining in lung tissue 
with DI 30-80%, and DI>80% as well as in LVR patients. Staining for other basement 
membrane associated components (type IV collagen and laminin) was not aberrant. 
Scale bars, 50 µm.
DI, destructive index; MLI, mean linear intercept
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Statistical analysis
Statistical analysis was done with tests for non-parametric data: Kruskal-Wallis (four 
groups), Spearman’s coefficient of rank correlation, and the Mann-Whitney U test for 
multiple comparisons. Data were analysed with the Statistical Package for the Social 
Sciences 12.01 (SPSS Inc., Chicago, IL), and GraphPad Prism®, version 4.0 (GraphPad 
Software Inc., San Diego, CA) computer programs. Values of P < 0.05 were considered 
significant.
Heparanase overexpressing mice
The homozygous mouse strain overexpressing human heparanase and the respective 
control  mice (C57BL background) were described previously by Prof. I. Vlodavsky 
and Dr. J-p Li [28]. In brief, full-length human heparanase cDNA was subcloned into 
pCAGGS plasmid at EcoRI-XbaI sites under constitutive control of the chicken β-actin 
promoter and expressed in all tissues. The plasmid was digested with SalI-PstI and the 
resulting linear fragment was microinjected to fertilised eggs of C57BL/6 x Balb/c origin 
to produce transgenic mice overexpressing the heparanase cDNA. 
Tissue processing
Each specimen (about 1 cm3) was cut into pieces of equal size. One part was immersed 
in phosphate buffered saline (PBS, pH 7.2), inflated under vacuum (13kPa) for 20 
min using a routine water stream-driven device (water aspirator) to restore alveolar 
dimensions [35], frozen in liquid nitrogen, and stored at -80°C. This part was used 
for immunohistochemistry (see below). The other part was similarly inflated in PBS 
containing 4% formalin and further processed for paraffin embedding. Sections (4-5 µm) 
were then cut, hematoxylin-eosin stained, and used for morphological characterisation. 
All sections were blinded and scored independently by two observers. 
Gene expression analysis 
To analyse gene expression in mice overexpressing heparanase (HPSEtg mice), lung 
samples of 70-day-old mice were used. Two lung samples of HPSEtg mice and two lung 
samples of the wildtype background (C57BL6 mice) were taken and snap frozen in liquid 
nitrogen and stored at -80°C. Frozen samples were grinded in a microdismembrator 
(Sartorius, Bunnik, the Netherlands) and RNA was isolated using the TRIZOL-method 
(Invitrogen, Paisley, UK) in combination with RNeasy Mini kit including a DNAse step 
(Qiagen, Hilden, Germany). RNA quality was checked using the Bioanalyzer system 
(Agilent Technologies, Amstelveen, the Netherlands). The RNA integrity numbers and 
the rRNA ratios were 7.6 and 1.0 respectively for the first transgenic sample; 6.5 and 
0.9 for the second transgenic sample; 6.8 and 0.9 for the first wild type sample; and 7.2 
and 1.0 for the second wild type sample, respectively. Based on criteria described by 
Schroeder et al. (2006) [36] the samples were of sufficient quality for gene expression 
analysis. cDNA was prepared from RNA samples using the Superscript III First-Strand 
Synthesis system (Invitrogen) with random hexamers. RNA-derived cDNA quality was 
evaluated by PCR (Fast start Taq polymerase, Roche, Almere, the Netherlands) using 
primers for GAPDH (Forward primer 5`-TGATGGGTGTGAACCACGAG-3` and reverse 
primer 5`-GGGCCATCCACAGTCTTCTG-3`). 
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Figure 3. A-B; Overexpression of heparanase initiates emphysematous lesions 
in mice. A: Mean Linear Intercept (MLI) values (mean ± SD, n = 6) of lungs of wild 
type (WT) and heparanase overexpressing mice (HPSEtg mice) at different ages. 
B: Hematoxylin-eosin stained sections of lungs from wild type and HPSEtg mice at 
different ages. In heparanase overexpressing mice enlargement of airspaces could 
be observed in lungs of 3-months-old mice, and this was increased with age. m = 
months. C; CD8 T-lymphocytes in lung parenchyma from subjects with microscopical 
emphysema expressed as percentage of total cell numbers (total number of nuclei) in 
lung parenchyma. Horizontal bars represent mean values (Mann-Whitney U test). D, 
Lung tissue from subjects with normal (left panel) and moderately affected lung tissue 
(right panel) demonstrating immunoreactivity for inflammatory cells (CD8 and CD4). 
Note the increase in CD4 and CD8 cells in moderately affected lung tissue.
**, P < 0.05; ***, P < 0.0001.
Scale bars, 50 µm. HPSEtg mice, heparanase overexpressing mice.
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Gene expression was analysed using Real Time-Quantitative PCR (QPCR) using 
custom designed Taqman Low Density arrays (TLDA) (Applied Biosystems, Nieuwekerk 
aan de IJssel, the Netherlands) containing probes for genes involved in production of 
precursors (53 genes); core proteins (28); preparation of linkage region (8 genes); 
glycosaminoglycan (GAG) chain polymerisation (13); GAG chain modification (32); 
GAG chain degradation (19); growth factors (19); genes with a putative role in GAG 
metabolism (15); and reference genes (5). An overview of the genes evaluated, including 
probe set numbers can be found in Supplementary data Table 1. 
For the TLDA carts, 100 ng cDNA in Taqman Universal PCR Master Mix (Applied 
Biosystems) was loaded per slot as described in the manufacturer’s protocol and run 
on a 7900HT Fast Real-Time PCR System (Applied Biosystems). Expression was 
analysed based on the threshold cycle (Ct) using SDS 2.3 software and RQ Manager 
1.2 (Applied Biosystems).
 In Microsoft Excel the reference genes 18S RNA, ActB, Gapdh, Hprt and Tbp, for 
dCt calculation were checked for stability of expression.  Each reference gene was 
used to calculate the dCt for the other reference genes. The average dCt and standard 
deviation across all carts was calculated. Based on this analysis three reference genes 
were found suitable based on an acceptable standard deviation  (maximal ±0.5), viz. 
ActB, GAPDH and TBP. Based on the average Ct across all carts a reference gene was 
chosen for a specific gene. For genes with a Ct between 26.5 and 34.5 Tbp (average 
Ct of 30.5) was used; for genes with a Ct between 19.6 and 27.6 Gapdh (average Ct 
of 23.6)  was used; and for genes with a Ct between 16.8 and 24.8 ActB (average 
Ct of 20.8) was used.  For some genes two separate dCt values were calculated 
based on two reference genes. dCT values were further processed applying the 2-ΔΔCT 
method using the wild type background (C57BL6 mice) data as the calibrator point 
[37]. Statistical significance was tested with an unpaired T-test (2-tailed) using Microsoft 
Excel. A statistical threshold of p<0.100 and a fold threshold of >1.5 were used. 
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Results 
Morphological data 
Lung specimens from 21 subjects were morphologically characterised for 
emphysematous lesions using the DI as a marker for early parenchymal destruction 
and the MLI as a marker for airspace enlargement (Table 1) [38]. Please note that for 
normal, unaffected lungs of non-smoking individuals in the fifth-sixth decade of life, 
the DI is between 0-30% [14]. Based on the DI, three groups were grouped as follows: 
1) normal tissue (DI<30%, MLI normal); 2) slightly affected tissue (DI 30-80%, MLI 
normal), and 3) moderately affected tissue (DI>80%, MLI increased). A comparison was 
made with lung specimens from patients with severe emphysema (LVR (lung volume 
reduction) patients, n = 3).
Reduced heparan sulfate expression is associated with 
early signs of parenchymal destruction
The expression of ECM components in the lung parenchyma of patients was 
evaluated by immunohistochemistry.  In lung tissue from patients without microscopic 
emphysema (DI<30%, MLI normal) HS was abundantly present in alveolar walls as 
well as in peribronchiolar and perivascular areas (Figure 1A, Figure 2A1 and Figure 
4D). However, in slightly affected tissue (DI 30-80%, MLI normal), a reduced and 
discontinuous staining for HS was observed in alveolar basement membranes, as well 
as in peribronchiolar and perivascular areas (Figure 1A, 2B1 and 4E). In moderately 
affected tissue (DI>80%, MLI increased), the reduction of HS in alveolar basement 
membranes was more pronounced (Figure 2C1 and 4F), whereas capillaries remained 
strongly positive (Figure 2C1). Staining for other basement membrane components such 
as type IV collagen and laminin and for the interstitial matrix components elastin and 
decorin (a dermatan sulfate proteoglycan) did not reveal differences in staining among 
the three groups (Figure 1, C-F and Figure 2, A4-D4 and A5-D5). Also, staining for type I 
collagen was not aberrant between groups (data not shown). In lung tissue derived from 
LVR patients the expression of HS was decreased (Figure 2, D1-D3) whereas staining 
for collagen IV and laminin was unaltered (Figure 2, D4-D5), as was staining for decorin 
(not shown).  
In normal tissue (DI<30%, MLI normal) heparanase could not be detected (Figure 
1B and Figure 4A). In contrast, heparanase expression was markedly increased in 
slightly as well as moderately affected lung tissue (Figure 1B and Figure 4, B and C). 
Heparanase expression was found in alveolar and peribronchiolar areas (primarily 
associated with epithelial cells), and in perivascular areas. Lung tissue derived from 
LVR patients showed an increase in heparanase expression (Figure 4Q).
Staining for the core protein of agrin, a major HS proteoglycan, revealed a continuous 
basement membrane staining in alveolar tissue, and in bronchiolar and vascular 
areas in normal tissue (Figure 2, A2 and A3). Discontinuous and reduced staining was 
observed in slightly affected tissue (Figure 2, B2 and B3), and was more prominent in 
moderately affected tissue (Figure 2, C2 and C3). Staining of capillaries was strongly 
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positive in tissues of all groups (Figure 2, C2 and C3). Strongly reduced staining for the 
core protein of agrin was also observed in lung specimens from LVR patients (Figure 2, 
D2 and D3).
Figure 4. Overexpression of heparanase is associated with loss of heparan sulfate (HS). 
A-F: morphologically analysed sections of subjects with normal (DI<30%, MLI normal 
A, D), slightly affected (DI 30-80%, MLI normal B, E), or moderately affected (DI>80%, 
increased MLI C, F) lung parenchyma were incubated with antibodies against human 
heparanase (A-C) or HS (D-F). Heparanase expression increased with DI in alveolar 
basement membranes (arrows), perivascular areas (arrowheads), and peribronchiolar 
areas (not shown), whereas HS decreased.
Scale bars, 50 µm. G-P: Lung tissue from wild type mice (G-O, 3 months old), and 
HPSEtg mice (H-P, 3 months old) were stained with antibodies against heparanase (G, 
H), HS (I, J), agrin core protein (K, L), laminin (M, N), and type IV collagen (O, P). Note 
the increase in heparanase and loss of HS in transgenic mice. Staining for other matrix 
components was not affected. Q: Expression of heparanase in lung tissue from LVR 
patients.
Scale bar, 50 µm. DI, destructive index;  HPSEtg mice, heparanase overexpressing 
mice.
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Microscopic emphysema is associated with increased 
CD4 and CD8 infiltration
Several reports have shown that in patients with emphysema an ongoing inflammatory 
process is present [39, 40]. We assessed inflammation in lung tissue from subjects 
without clinically evident airflow limitation by the number of CD4 and CD8 T-lymphocytes. 
We found that subjects with moderately affected tissue (DI>80%, MLI increased) showed 
more CD4 and CD8 T-lymphocytes in lung parenchyma compared to subjects with 
slightly affected tissue (DI 30%-80%, MLI normal). Also, subjects with slightly affected 
tissue (DI 30%-80%, MLI normal) demonstrated more CD4 and CD8 T-lymphocytes in 
lung parenchyma compared to normal tissue (DI<30%, MLI normal) (Figure 3C, D).
Heparanase overexpression induces emphysematous 
lesions
To investigate whether airspace enlargement and emphysematous lesions could be 
initiated by overexpression of heparanase, an enzyme that degrades HS, we examined 
the lungs of transgenic mice overexpressing mammalian heparanase. Mice aged from 3 
months to 3 years were studied (Figure 3). In heparanase overexpressing mice, the MLI 
increases significantly over time. Compared to wild type mice at 3 months of age, the 
MLI in heparanase overexpressing mice increased 1.6-fold (1.59 ± 0.13 versus 0.97 ± 
0.07 in wild types; P < 0.0001, n = 6), and up to 2.2-fold (2.61 ± 0.13 versus 1.17 ± 0.06 
in wild types; P < 0.0001, n = 6) was noted in 3-year-old mice. Figure 3B clearly shows 
the presence of enlarged airspaces in lung sections from heparanase overexpressing 
mice. 
Using immunohistochemistry we evaluated heparanase expression in lungs from wild 
type versus HPSEtg mice. Heparanase could not be detected in wild type mice (Figure 
4G), whereas in heparanase overexpressing mice it was abundantly present throughout 
the lungs (Figure 4H). As expected, HS expression was greatly reduced in heparanase 
overexpressing mice (Figure 4 I, J). Staining intensity for other basement membrane 
components such as the core protein of agrin (Figure 4, K and L), laminin (Figure 4, 
M and N), and interstitial components such as elastin (data not shown) and collagen 
(type IV collagen, Figure 4, O and P) did not differ between wild type and heparanase 
overexpressing mice.
In addition to immunohistochemistry we evaluated gene expression in heparanase 
overexpressing mice (Supplementary data Table 1), focussing on genes involved in 
the metabolism of glycosaminoglycans. Four genes were found to be differentially 
expressed, three of them involved in HS biosynthesis, viz.: HS 3-O-sulfotransferase 
3a1 (Hs3st3a1), HS 6-O-sulfotransferase 1 (Hs6st1) and GlcNAc-Proteoglycan-4-Beta-
GlcA-transferase (Ext1) at 2.1, 1.6 and 1.7-fold respectively (Table 2). The fourth gene 
found to be significantly differentially expressed was beta-glucuronidase (GusB) at 1.6-
fold. GusB is involved in the degradation of HS. These results suggest that at the mRNA 
level a number of HS biosynthetic genes are upregulated resulting in structurally altered 
HS. In addition a number of other genes were differentially expressed, including Pgm1, 
Pgm2, Slc2a9, Slc34a4, Slc35b1, Ugp2, Aspn, Chst5, Chst8 and Pdgfa (Supplementary 
data Table 1).
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Discussion 
This study shows that loss of HS and increased expression of heparanase are associated 
with early signs of emphysema. Overexpression of heparanase, resulting in loss of HS, 
induced age-related emphysematous lesions in mice.
HS is increasingly considered as a regulatory polysaccharide, binding and modulating 
a number of effector molecules and ECM components. It has been coined “master 
regulator of interactions” [41]. HS interacts with various classes of proteins that are 
involved in the pathogenesis of emphysema. These include proteases and protease 
inhibitors [42], enzymes involved in neutralising reactive oxygen species like superoxide 
dismutase [43–47] and xanthine oxidase [47–49], chemokines [50], and growth factors/
cytokines [12, 51]. In addition, HS proteoglycans interact with basement membrane 
components, which is necessary for basement membrane barrier integrity in pulmonary 
tissue. Diminished presence of HS and agrin in the lungs may therefore affect basement 
membrane integrity. In animal models HS proteoglycans have been implicated in the 
pathogenesis of emphysema. Specific inhibition of proteoglycan synthesis induces 
emphysematous lesions in rats [52]. In elastase-induced emphysema in rats, HS is 
readily removed from the lung by degradation of the protein core of the HS proteoglycans 
[53], and as a consequence the protective, protease (elastase) inhibiting capacity of HS 
[54] is lost. Elastase-induced emphysema can be prevented by administration of HS 
[54]. The only long-lasting change (one year) observed in elastase-induced emphysema 
is a decrease in the ratio HS/collagen and HS/elastin [55]. HS can be depolymerised 
by reactive oxygen and nitrogen species [56] both present in cigarette smoke, and 
reactive oxygen species can induce the expression of heparanase [57]. Additionally, 
rats exposed to cigarette smoke show a decrease in HS content in the lung [58]. 
In lungs of human emphysematous patients biochemical alterations in glycosaminoglycans 
composition, including HS, have been observed [59, 60] but the results are contradictory. 
In line with previous work [61], the present study confirms a diminished HS staining in 
patients with clinically evident emphysema, and extent this observation to parenchymal 
lung tissue characterised by early signs of parenchymal tissue destruction i.e. tissue 
with a normal LMI value, but an increase DI index. We also found diminished agrin, a 
HS-proteoglycan present in basement membranes of parenchymal lung tissue, whereas 
staining for other basement membrane-specific components remained unaltered. 
All subjects included in this study are current or ex-smokers. During smoke exposure, 
the lungs are continuously exposed to numerous amounts of oxidants and free radicals. 
This phenomenon, which is known as oxidant stress [62, 63] is also believed to be a 
central factor in the pathogenesis of emphysema. Previous studies have shown that 
reactive oxygen species (ROS) are  able to degrade proteoglycan core proteins [64, 65] 
and glycosaminoglycans including HS and heparin [66–70]. Apart from HS degradation, 
ROS are able to inhibit de novo synthesis of proteoglycans [64–66, 69, 71]. ROS 
could therefore have a direct toxic effect in the alveolar wall resulting in, for example, a 
structurally altered HS. We observed alteration in HS biosynthetic enzymes which is in 
line with modified HS structures.  
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An important inflammatory process is present in central and peripheral airways of 
subjects with COPD [8, 72–74] and studies have demonstrated that it is mainly the CD8-
positive cell subset that increases in number in these patients [72, 73]. Here, where 
we used tissue from subjects with early signs of tissue destruction, we found higher 
numbers of CD8 and CD4 T-lymphocytes in moderately affected lung tissue (DI>80%; 
MLI increased) when compared to slightly affected tissue (DI 30-80%; MLI normal) 
and normal tissue (DI<30%; MLI normal), further indicating the role of immune cells in 
parenchymal destruction [75]. 
We have implicated a role for HS in the onset and early stages of emphysema. If there is 
a correlation between the onset of emphysema and HS, it is possible that HS expression 
could be used as a diagnostic tool to detect emphysema at an earlier stage than current 
methods. In normal functioning tissue HS binds ligands and thereby modulates cell 
signalling and cell migration [23]. Aberrant amounts or structure of HS may lead to 
malfunction. For example, NDST1 deficient endothelial cells display poorly sulfated HS, 
leading to impaired neutrophil trafficking due to impaired binding of L-selectins to HS 
[76]. The interaction between HS and selectins could be of importance for leukocytes 
as well, since these cells also display selectins. It has been reported that selectins on 
leukocytes interact with HS presented on the blood vessel wall, which stops the migration 
of leukocytes and allows transmigration across the blood vessel wall and subsequently 
regulate the inflammatory response [18]. As shown in the NDST1 deficient endothelial 
cells, a small change in HS sugar chain modifications leads to impaired binding of HS to 
selectins. This suggestion seems to be in accordance with a study by Oudijk et al. (2003) 
in which the authors speculate that improper homing of leukocytes causes inflammation 
in the surrounding tissue [77]. The improper homing could be a result of hampered 
binding to HS. In addition to the role of HS in the inflammatory response, a role in the 
maintenance of stem cells has been suggested [26]. The basal membrane beneath 
type II alveolar stem cells contains a specific amount of sulphation. It is possible that 
Table 2. Differential expression of genes involved in the metabolism of glycosaminoglycans 
in HPSEtg 
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due to the increased expression of sulfotransferases the level of sulphation of the basal 
lamina is altered, leading to aberrant stem cell function.  To investigate the role of HS in 
the regulation of the inflammatory responses during the onset of emphysema additional 
research is required. This research should be focussed on the sugar level. The gene 
expression data of  HPSEtg mice presented in this study, together with gene expression 
data on heparanase mouse skin (results not shown) and results of an EXTL2-null mouse 
model [78], gene expression levels are suggested to be only slightly affected, while at 
the sugar level modifications lead to clearly distinguishable effects. 
 In conclusion, our results provide a clear link between heparanase, HS and pulmonary 
emphysema. We demonstrated that in human lung parenchyma heparanase is 
overexpressed at an early stage of tissue destruction. Of note, overexpression of 
heparanase in mice causes emphysematous lesions, which become more severe 
over time as they do in the human situation. Increased heparanase expression may 
therefore be a crucial early pathogenic event in emphysema, and may be a promising 
pharmacological target. Currently, a number of heparanase inhibitors such as PI-
88, PG545 and Roneparstat are in clinical trials for their capacity to inhibit cancer 
progression, angiogenesis and metastasis [79, 80] . Heparanase may be an attractive 
pharmacological target because it appears that only one form of heparanase is present, 
in contrast to e.g. the family of matrix metalloproteinases. Therefore, understanding the 
role of heparanase and HS in the onset of emphysema may lead to new therapeutic 
approaches to control this disease.
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Summary
Based on the observation that skin heals without a scar during embryonic development, 
we investigated the possibilities of using principles found in embryonic development 
to design novel constructs. Such constructs may induce embryonic-like processes, 
potentially, and result in scarless healing when used for the treatment of full-thickness 
skin wounds. Current treatments often result in scar tissue, which shows reduced 
functionality and elasticity in comparison to undamaged skin. The aim of the research 
was to elucidate effector molecules involved in skin development and to incorporate 
these effector molecules into a type I collagen-heparin scaffold. In addition, novel 
techniques and methods were developed to analyse/construct these scaffolds. 
In preparation of this investigation a literature study (Chapter 1) was performed, in 
which the current status of various aspects involved in embryonic skin development 
and scarless healing was indicated.  We focused on the upper two layers of skin, i.e. the 
epidermis and dermis, and appendages such as hair follicles. Since the construct will be 
used to treat skin wounds, adult wound healing was studied, which is characterized by 
four stages, i.e. haemostasis, inflammation, proliferation and remodeling, and compared 
to wound healing as found during embryonic development. This comparison revealed 
several points to take in account during the design of the embryonic-like scaffold. In 
addition, the current status of skin tissue engineering is discussed. The last part of 
the literature study as described in Chapter 1 reports on glycosaminoglycan (GAG) 
synthesis and degradation, since these extracullular matrix (ECM) components are 
used in the construct and are a central part of Chapter 5 and Chapter 6. 
Based on the findings on skin development two time points in embryonic development, 
i.e. 14 days post conception (E14) and E16, and one postnatal time point, i.e. one day 
post birth (P1), were selected to compare gene expression with  adult skin (P90) using 
EXON arrays. This comparison, as described in Chapter 2, resulted in a list of 20 growth 
factors, of which two were selected, i.e. insulin-like growth factor 2 (Igf2) and sonic 
hedgehog (Shh), which were successfully incorporated into a type I collagen-heparin 
scaffold. In addition, we created type I collagen scaffolds containing hyaluronic acid, 
since hyaluronic acid is found in embryonic skin and is suggested to be important during 
embryonic wound healing.
In Chapter 3 we present a method which allows the discrimination of newly formed 
collagen and implanted collagen, using a single-chain antibody GD3A12. This antibody 
recognizes dermatan sulfate (DS)  which is strongly associated with newly synthesized 
collagen. This method offers a solution for the detection of newly formed collagen  after 
construct implantation.
During embryonic development gradients of effector molecules are important. It 
is therefore of interest to create a type I collagen scaffold containing a gradient of 
effector molecules. In Chapter 4 results are presented of the development of a scaffold 
containing a gradient of heparin, a GAG. Subsequent incubation with fibroblast growth 
factor 2 resulted in a gradient of this effector molecule.
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Given the importance of GAGs in the binding and gradient formation of effector 
molecules, we investigated the role or GAGs during skin development by studying gene 
expression using the EXON array  data and a  customly designed taqman low density 
array (TLDA cart) containing a large number of  genes involved in GAG biology. In 
addition we analysed the gene expression in two mouse models, i.e. a glucuronic acid 
epimerase knockout mouse and a heparanase overexpression mouse. The results, as 
presented in Chapter 5, showed that a dynamic gene expression pattern during skin 
development. 
The last chapter, Chapter 6, does not focus on skin, but on the lung. This chapter 
indicates the importance of degradation of GAGs in relation to tissue destruction. 
The general finding was that increase of heparanase and loss of heparan sulfate is 
associated with the development of lung emphysema. Gene expression data  showed 
a number of genes differentially expressed, e.g. 3-O and 6-O sulfotransferase and an 
enzyme involved in GAG chain degradation.
Overall we have set the first steps in the construction of embryonic scaffolds for tissue 
engineering, focusing on glycosaminoglycans, effector molecules and collagen. In 
addition we have developed/extended methodologies for analysis and evaluation.
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General discussion and future 
perspectives
The results presented in this thesis show that we have successfully elucidated 20 
embryonic specific effector molecules involved in embryonic skin development and 
incorporated two, i.e. Igf2 and Shh into a type I collagen-heparin construct. Although 
not part of this thesis, we evaluated the construct in vivo in a mouse wound model using 
8 mm biopsy punches and results were analyzed after 7, 21 and 90 days. The results of 
these experiments, however, showed numerous problems with the experimental setup 
and various technical difficulties were encountered. We therefore decided not to include 
these results in this thesis. 
The main problem we encountered was contraction of the wound. Murine wound healing 
shows more and faster contraction [1,2], which influenced the effect of the scaffold. 
In future research a model system must be chosen that shows wound contraction 
comparable to human wound healing. Alternatively the wound size could be enlarged, 
to prevent contraction. A porcine skin model is probably more suitable, since pig skin is 
more comparable to human skin than mouse skin [3,4].
In addition we tested only two effector molecules of a list of 20, i.e. insulin-like growth 
factor 2 (Igf2) and sonic hedgehog (Shh). It is my opinion that all discovered effector 
molecules should be tested on inducing embryonic-like signaling in adult epidermal and 
dermal cells. Initially these tests could be completed in vitro using keratinocytes and 
fibroblasts. In this more controlled environment the effect of these growth factors can 
be studied in more detail and the optimal concentration for activation of the signaling 
pathways could be determined. The most suitable candidates should subsequently be 
tested in vivo in a mouse or porcine wound model or implanted subcutaneously [2]. The 
effect of the scaffold should be tested using standard histology and immunohistochemistry 
to analyse the new tissue formation and possibly the formation of new appendages. 
Furthermore gene expression should be assessed to determine if the incorporated 
effector molecules indeed activated embryonic-like processes. 
The presented research focused on a type I collagen-heparin construct. In literature on 
scarless healing, however, other components are presented which may be of interest 
for an alternative scaffold that represents the embryonic ECM more in comparison to 
the used scaffold [5,6]. Therefore the created type I collagen-hyaluronic acid scaffold 
could be of interest, since it may mimic the embryonic environment and, in combination 
with the embryonic effector molecules, result in embryonic-like processes. An expected 
problem, however, is the lack of sulfation in hyaluronic acid, which may hamper the 
binding of effector molecules [7]. Making a combination of hyaluronic acid and heparin 
could circumvent this problem.
Addition of type III collagen to the scaffold may make the scaffold more embryonic-like 
as well. Type I collagen is the most predominant collagen in both embryonic as adult 
skin, but is supplemented by type III collagen [8]. In embryonic skin, type III collagen is 
present at a higher percentage when compared to adult skin. The isolation of type III 
collagen, however, is hampered by the fact that collagen type I is the main collagen in 
the ECM. Recombinant produced type III collagen may offer an alternative [9], although 
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this option may be hampered by the lack of post-translational modifications in yeast [10].
We have shown to be able to create a gradient of effector molecules. But as described in 
Chapter 3, the dimension of the gradient is too large with respect to the gradients found 
in nature [11,12]. Alternative strategies, such as a microfluidic system as suggested 
in Chapter 3 or 3D printing [13], should be explored as gradients are essential for 
embryonic development [14,15]. 
The second part of this thesis predominantly deals with glycosaminoglycans (GAGs). 
We studied GAG biology using gene expression analysis. We started using the rationale 
that gene expression provides information about  modification of the GAG sugar chains 
[7,16]. Expression data, however, suggested a more complex story. One of the possible 
reasons could be that expression of GAG related genes may be regulated by IRES 
sites [17–19], an alternative transcription method, which allows transcription during cell 
division. Transcription normally takes place during the G1/S-phase of cell division [19]. 
Another reason could be differences in enzyme activity, as was found for the different 
Ndst isoforms [20]. The bottom line is, that the process from DNA to functional GAGs  is 
complex and regulated at multiple levels. Identification of specific GAG domains involved 
in the binding of effector molecules could be quite rewarding. Current technologies 
to sequence and synthesize GAGs, however, are cumbersome. Further research is 
therefore needed, to develop and enhance GAG analysis techniques and subsequently 
use them to study the role of GAGs during embryonic development, and their use in 
embryonic scaffolds for regenerative medicine. 
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Samenvatting
Gebaseerd op de observatie dat huid zonder litteken geneest tijdens de embryonale 
ontwikkeling, hebben we de mogelijkheid onderzocht om principes te gebruiken, 
zoals gevonden tijdens de embryonale ontwikkeling, voor het ontwerp van nieuwe 
constructen. Dergelijke constructen zouden mogelijk embryonaal-achtige processen 
kunnen induceren en resulteren in herstel zonder litteken als deze worden gebruikt 
voor de behandeling van wonden waarbij zowel de epidermis als dermis beschadigd 
zijn. Huidige behandelingen leiden vaak tot littekenweefsel, dat minder functionaliteit 
en elasticiteit laat zien als je dit vergelijkt met onbeschadigde huid. Het doel van dit 
onderzoek was het ophelderen van effector-moleculen betrokken bij de huid ontwikkeling 
en het incorporeren van deze moleculen in een type I collageen-heparine-matrix. 
Daarnaast zijn er nieuwe technieken en methoden ontwikkeld om deze constructen te 
construeren en te analyseren. 
Als voorbereiding op dit onderzoek is er een literatuurstudie gedaan (Hoofdstuk 1), 
waarin de huidige status van verschillende aspecten betrokken bij embryonale huid 
ontwikkeling en genezing zonder litteken zijn aangegeven. Bij dit onderzoek is er 
met name gekeken naar de twee bovenste lagen van de huid, dat wil zeggen de 
epidermis en de dermis, en appendages zoals haarfollikels. Aangezien de constructen 
gebruikt zullen worden om huidwonden te behandelen, is er daarnaast gekeken naar 
volwassen wondgenezing, welke zich kenmerkt door vier stadia, namelijk heamostase, 
ontsteking, proliferatie en remodellering. De volwassen wondgenezing is vergeleken 
met wondgenezing zoals gevonden tijdens embryonale ontwikkeling, waarbij diverse 
aspecten zijn gevonden waarop gelet moet worden bij het ontwerp van de embryonaal-
achtige constructen. Verder is er gekeken naar de huidige stand van zaken van huid 
tissue-engineering. Hoofdstuk 1 wordt afgesloten met een overzicht van de synthese 
en afbraak van glycosaminoglycanen (GAG), aangezien deze componenten van de 
extracellulaire matrix (ECM) verwerkt worden in het construct en centraal staan in 
Hoofdstuk 5 en Hoofdstuk 6.
Gebaseerd op de gegevens over de huid ontwikkeling zijn er twee tijdstippen tijdens de 
embryonale ontwikkeling, namelijk viertien dagen na conceptie (E14) en E16, en één 
postnataal tijdstip, namelijk één dag na geboorte (P1), geselecteerd om genexpressie 
te vergelijken met volwassen huid (P90), waarbij gebruik is gemaakt van EXON arrays. 
Deze vergelijking, zoals beschreven in Hoofdstuk 2, heeft geresulteerd in een lijst 
van twintig groeifactoren. Twee groeifactoren uit deze lijst zijn geselecteerd, namelijk 
insulin-like growth factor 2 (Igf2) en sonic hedgehog (Shh), en deze zijn succesvol 
geïncorporeerd in een type 1 collageen-heparine-matrix. Daarnaast hebben we type 1 
collageen-matrices gemaakt waarin hyaluron zuur is verwerkt, aangezien hyaluron zuur 
aanwezig is in de embryonale huid en mogelijk een rol speelt tijdens embryonale wond 
genezing.
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In Hoofdstuk 3 wordt een methode gepresenteerd die het toelaat om nieuw gevormd 
collageen en geïmplanteerd collageen te onderscheiden, waarbij gebruik gemaakt wordt 
van het single-chain antilichaam GD3A12. Een single-chain antilichaam is een hetero-
dimeer van het variabele gedeelte van de lichte keten en het variabele gedeelte van 
de zware keten van een immunoglobuline molecuul. Het antilichaam herkent dermatan 
sulfaat (DS), die sterk verbonden is met nieuw gevormd collageen. Deze methode biedt 
een oplossing voor de detectie van nieuw gevormd collageen na implantatie van een 
type 1 collageen-construct.
Tijdens de embryonale ontwikkeling spelen gradiënten van effector moleculen een 
belangrijke rol. Het is daarom interessant om type 1 collageen-constructen te creëren 
die een gradiënt van effector moleculen bevatten. In Hoofdstuk 4 worden resultaten 
gepresenteerd van de ontwikkeling van een type 1 collageen-matrix met een gradiënt 
van heparine, een GAG. Incubatie met fibroblast growth factor 2 resulteerde in een 
gradiënt van dit effector molecuul. 
Aangezien GAGs belangrijk zijn voor de binding en de gradiënt formatie van effector 
moleculen, hebben we onderzocht wat de rol van GAGs is tijdens huidontwikkeling door 
te kijken naar genexpressie gebruikmakend van EXON array-data en een handmatig 
ontworpen taqman low density array (TLDA kaart), met daarop een groot aantal genen 
betrokken bij GAG biologie. Daarnaast is de genexpressie geanalyseerd van twee 
muismodellen, namelijk een glucuron zuur epimerase knockout muis en een heparanse 
overexpressie muis. De resultaten, zoals gepresenteerd in Hoofdstuk 5, laten een 
dynamisch genexpressie patroon zien tijdens de embryonale huidontwikkeling. 
Het laatste hoofdstuk, Hoofdstuk 6, richt zich niet op de huid, maar op de long. Dit 
hoofdstuk geeft het belang aan van GAG degradatie in relatie tot weefsel destructie. De 
algemene bevinding was dat de toenamen van heparanase en het verlies van heparan 
sulfaat verbonden is met de ontwikkeling van longemfyseem. Genexpressie data laten 
zien dat een aantal genen verschillend tot expressie komt, waaronder 3-O en 6-O 
sulfotransferases en een enzym betrokken bij GAG degradatie.
Samenvattend hebben we de eerste stappen gezet voor de constructie van embryonaal-
achtige constructen voor tissue-engineering, waarbij gefocust is op glycosaminoglycanen, 
effector moleculen en collageen. Daarnaast hebben we methodologieën ontwikkeld 
voor het analyseren en evalueren van deze constructen.
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Algemene discussie en Toekomstvisie
De resultaten zoals gepresenteerd in dit proefschrift laten zien dat we met succes 
20 embryonaal-specifieke effector moleculen hebben opgehelderd betrokken bij de 
embryonale huid ontwikkeling, waarvan twee, namelijk Igf2 en Shh, geïncorporeerd 
zijn in een type 1 collageen-heparine-construct.  Alhoewel het geen onderdeel is van 
dit proefschrift, hebben we het construct geëvalueerd in vivo in een muis wondmodel, 
waarbij gebruik gemaakt is van 8 mm huidstansen en de resultaten zijn geanalyseerd 
na 7, 21 en 90 dagen. De resultaten van de experimenten echter toonde verschillende 
problemen met de gekozen experimentele aanpak en er zijn verschillende technische 
problemen naar voren gekomen. Er is daarom gekozen deze resultaten niet op te 
nemen in dit proefschrift.
Het belangrijkste probleem dat naar voren kwam was de contractie van de wond. 
Wondgenezing bij de muis laat meer en snellere contractie zien [1,2], die het effect 
van het construct beïnvloedt. In toekomstig onderzoek moet een modelsysteem 
gekozen worden die wondcontractie heeft vergelijkbaar met wondgenezing bij de mens. 
Het is ook mogelijk de wondgrootte te vergroten om contractie te voorkomen. Een 
varkenshuidmodel is waarschijnlijk het meest geschikt, aangezien varkenshuid meer 
vergelijkbaar is met mensenhuid dan muizenhuid [3,4].
Verder zijn enkel twee van de lijst van twintig effector moleculen getest, namelijk 
insulin-like growth factor 2 (Igf2) en sonic hedgehog (Shh). Het is mijn mening dat 
alle ontdekte effector moleculen getest zouden moeten worden op het induceren 
van embryonaal-achtige signalering in adulte epidermale en dermale cellen. Initieel 
zouden deze test in vitro gedaan kunnen worden waarbij gebruik gemaakt wordt van 
keratinocyten en fibroblasten. In deze meer gecontroleerde omgeving is het effect 
van deze groeifactoren meer in detail te bestuderen en kan de optimale concentratie 
voor het activeren van signaleringcascades bepaald worden. De meest geschikte 
kandidaten zouden vervolgens getest kunnen worden in vivo in een muis- of 
varkenswondmodel of subcutaan geïmplanteerd kunnen worden [2]. Het effect van het 
construct zou vervolgens getest kunnen worden met behulp van standaard histologie 
en immunohistochemie, om te analyseren of er nieuw weefsel en mogelijk nieuwe 
appendages zijn gevormd. Daarnaast zou genexpressie gemeten moeten worden om 
te bepalen of de geïncorporeerde effector moleculen daadwerkelijk embryonaal-achtige 
processen heeft geactiveerd. 
Het gepresenteerde onderzoek richtte zich op de ontwikkeling van een type 1 collageen-
heparine-construct. In de literatuur over wondgenezing zonder litteken staan echter 
andere componenten die mogelijk interessant zijn voor een alternatief construct ontwerp 
dat beter de embryonale ECM representeert in vergelijking met het gebruikte construct 
[5,6]. Daarom is het ontwikkelde type 1 collageen-hyaluron zuur construct interessant, 
aangezien deze mogelijk de embryonale omgeving beter nabootst en kan resulteren in 
embryonaal-achtige processen in combinatie met de embryonale effector moleculen. 
Een verwacht probleem is echter het gebrek aan sulfetering van hyaluron zuur, wat de 
binding van effector moleculen kan bemoeilijken [7]. Het maken van een combinatie van 
hyaluron zuur en heparine zou dit probleem kunnen oplossen. 
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Het toevoegen van type 3 collageen aan de scaffold zou de scaffold ook meer embryonaal-
achtig kunnen maken. Type 1 collageen is de meest voorkomende collageen in zowel 
de embryonale als de adulte huid, maar bevat ook type 3 collageen [8]. In embryonale 
huid is het percentage aanwezige type 3 collageen hoger in vergelijking met adulte 
huid. The isolatie van collageen type 3 wordt echter belemmerd doordat type I collageen 
het belangrijkste type collageen is in de ECM. Recombinant geproduceerde type III 
collageen zou een alternatief kunnen bieden [9], maar deze optie is beperkt door het 
gebrek aan post-translationele modificaties in gist [10].
We hebben getoond dat het voor ons mogelijk is om een gradiënt van effector moleculen 
te creëren. Maar, zoals beschreven in Hoofdstuk 3,  de afmetingen van de gradiënt zijn 
te groot in vergelijking met de gradiënten zoals gevonden in de natuur [11,12]. Een 
alternatieve strategie, zoals het in Hoofdstuk 3 gesuggereerde microfluidic systeem of 
3D printen [13], zou onderzocht moeten worden aangezien gradiënten essentieel zijn 
voor embryonale ontwikkeling [14,15].
Het tweede deel van dit proefschrift gaat voornamelijk over glycosaminoglycanen 
(GAGs). We hebben de GAG biologie bestudeerd met genexpressie analyse. We zijn 
gestart met het gebruiken van de redenering dat genexpressie informatie doorgeeft over 
de modificatie van de GAG suiker keten [7,16]. Expressie data suggereren echter een 
meer complex verhaal. Een mogelijke reden zou kunnen zijn dat expressie van GAG 
gerelateerde genen gereguleerd is met IRIS sites [17–19], een alternatieve transcriptie 
methode, die toelaat dat transcriptie plaats vindt tijdens de celdeling. Transcriptie 
vindt normaal gesproken alleen tijdens de G1/S-fase van de celdeling plaats [19]. Een 
andere reden zou verschillen in enzym activiteit kunnen zijn, zoals gevonden voor de 
verschillende Ndst isoformen [20]. Het komt erop neer dat het proces van DNA tot 
functionele GAGs complex is en gereguleerd is op meerdere niveaus. Identificatie van 
specifieke GAG domeinen betrokken bij het binden van effector moleculen zou zeer 
belonend kunnen zijn. Huidige technieken om de sequentie van GAGs te bepalen of 
om GAGs te synthetiseren zijn echter omslachtig. Verder onderzoek is daarom nodig 
om GAG analyse technieken te ontwikkelen en te verbeteren om deze vervolgens te 
gebruiken om de rol van GAGs tijdens de embryonale ontwikkeling en de toepassing van 
GAGs in embryonale constructen voor de regeneratieve geneeskunde te bestuderen.
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2008  0.5 
f) Supervision of internships / other
‐ Supervision bachelor student, Astrid Swinkels 
‐ Supervision practical course Tissue engineering P004 
‐ Supervision practical course Biochemistry for first years 
students 
‐ Supervision of master student, Petra Lücker 
‐ Co‐supervision of master student, Ralph Jaspers 
‐ Supervision of bachelor student (HAN), Rouven 
Schoppmeer 
2006 
2006‐2009 
2006‐2009 
2008 
2008 
2010 
1.5 
1 
1 
1.5 
0.5 
1.5 
TOTAL  34 
Ph.D. portfolio
Chapter 8
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